Document:

Investor Rights Agreement

 Exhibit 4.3 
 [Execution Copy] 
 INVESTOR RIGHTS AGREEMENT 

This INVESTOR RIGHTS AGREEMENT (the “Agreement”) is made as of June 30, 1999 by and among Paratek Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), and Glaxo Group Limited, a corporation organized under the laws of England (the “Purchaser” or the “Investor”). 

WHEREAS, the Investor has purchased shares of Series B Convertible Preferred Stock, par value $.001 per share (the “Series B
Preferred Stock”), pursuant to a Preferred Stock Purchase Agreement dated as of even date hereof by and between such Investor and the Company (the “Purchase Agreement”); and 

WHEREAS, as a condition to entering into the Purchase Agreement, the Company and the Investor desire to provide for certain registration
and other rights as set forth herein; 
 NOW, THEREFORE, in consideration of the premises and mutual agreements set forth herein
and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties hereto agree as follows: 
  

	1.	GENERAL PROVISIONS 

 1.1 Shares Subject
to this Agreement. The Investor expressly agrees that the terms and restrictions of this Agreement shall apply to all shares of capital stock which any of them now owns or hereafter acquires by any means, including without limitation by
purchase, assignment or operation of law, or as a result of any stock dividend, stock split, reorganization, reclassification, whether voluntary or involuntary, or other similar transaction, and to any shares of capital stock of any successor in
interest of the Company, whether by sale, merger, consolidation or other similar transaction, or by purchase, assignment or operation of law (the “Shares”). 
 1.2 Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 
 “Affiliate” has the meaning ascribed to that term in Rule 12b-2 under the Exchange Act, or any successor rule. 
 “Commission” shall mean the Securities and Exchange Commission and any successor agency of the Federal government administering the Securities Act and the Exchange Act. 

“Common Stock” shall mean (i) the common stock, $.001 par value per share, of the Company, (ii) any other
capital stock of the Company, however designated, authorized on or after the date hereof, which shall neither be limited to a fixed sum or percentage of par value in respect of the rights of the holders thereof to participate in dividends nor
entitled to a preference in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of the Company; and (iii) any other securities into which or for which any of the securities described in
(i) or (ii) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, consolidation, sale of assets or other similar transaction. 

 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended,
and any similar or successor Federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect from time to time. 
 “Initial Public Offering” shall mean the first underwritten public offering of Common Stock of the Company, offered on a firm commitment basis pursuant to a registration statement filed
with the Commission under the Securities Act on Form S-1 or its then equivalent, in which the aggregate net proceeds to the Company equals or exceeds $15,000,000. 
 “Person” means an individual, corporation, partnership, joint venture, trust or unincorporated organization, or a government or any agency or political subdivision thereof. 

The terms “register”, “registered” and “registration” shall refer to a registration
effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement, or, as the context
may require, under the Exchange Act or applicable state securities laws. 
 “Registrable Securities” shall mean
(i) shares of Common Stock or other securities issued or issuable pursuant to the conversion of the Series B Preferred Stock and (ii) any shares of Common Stock or other securities issued or issuable pursuant to the conversion of the
Series B Preferred Stock upon any stock split, stock dividend, recapitalization, reorganization, merger, consolidation, sale of assets or similar event, excluding in any event securities which (a) have been registered under the Securities Act
pursuant to an effective registration statement filed thereunder and disposed of in accordance with the registration statement covering them, (b) have been publicly sold pursuant to Rule 144 under the Securities Act, or (c ) are eligible for
resale pursuant to Rule 144 under the Securities Act. Wherever reference is made in this Agreement to a request or consent of holders of a certain percentage of Registrable Securities, the determination of such percentage shall be calculated on the
basis of shares of Common Stock issued or issuable upon conversion of the Series B Preferred Stock even if such exercise has not been effected. Notwithstanding the foregoing, nothing in this Agreement shall require the Company to register any shares
of Series B Preferred Stock. 
 “Registration Expenses” shall mean the expenses so described in
Section 3.3. 
 “Registration Statement” shall mean any registration statement for a secondary offering of
securities which the Company is eligible to file, other than a registration statement on Form S-4 or Form S-8, or successor or comparable forms thereto. 
 “Securities Act” shall mean the Securities Act of 1933, as amended, and any similar or successor Federal statute, and the rules and regulations of the Commission thereunder, all as the
same shall be in effect from time to time. 
 “Selling Expenses” shall mean the expenses so described in
Section 3.3. 

  
 2 

	2.	RESTRICTIONS ON TRANSFER OF SECURITIES 

2.1 Restrictive Legends. Each certificate representing the Series B Preferred Stock and the Registrable Securities shall, except as otherwise
provided in this Section 2.1, be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legend required under applicable state securities laws): 

“The securities represented by this certificate have not been registered under the Securities Act of 1933 or any other securities
laws. These securities have been acquired for investment and not with a view to distribution or resale. Such securities may not be offered for sale, sold, delivered after sale, transferred, pledged or hypothecated in the absence of an effective
registration statement covering such securities under the Securities Act of 1933 and any other applicable securities laws, unless the holder shall have obtained an opinion of counsel reasonably satisfactory to the corporation that such registration
is not required.” 
 Upon request of a holder of such a certificate, the Company shall remove the foregoing legend from the
certificate or issue to such holder a new certificate therefor free of such legend, if there is an effective registration statement covering the securities represented by such certificate or, with such request, the Company shall have received either
(i) an opinion of counsel reasonably satisfactory to the Company to the effect that the proposed sale, pledge, hypothecation or other transfer may be effected without registration under the Securities Act or (ii) a “no action”
letter from the Commission to the effect that the distribution of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto. 

In addition, each certificate representing the Series B Preferred Stock and the Registrable Securities shall bear a legend substantially
similar to the following: 
 “The shares represented hereby are also subject to restrictions on transfer contained in a
certain Preferred Stock Purchase Agreement, and may not be sold, pledged or otherwise transferred without compliance with the terms thereof. The Company will furnish a copy of the full text of such restrictions to the holder of this certificate upon
written request and without charge.” 
  

	3.	REGISTRATION 

 3.1 Registration.

 (a) After the Initial Public Offering and when the Company is eligible to file a Registration Statement, one or more of
the holders of Registrable Securities constituting at least 33-1/3% of the total shares of Registrable Securities then outstanding, may, on one occasion only, request that the Company file such Registration Statement for a public offering of all or
any portion of the shares of Registrable Securities held by such requesting holder or holders. Upon the receipt of notice of such request, the Company shall use its best efforts to register under the Securities Act on such Registration Statement for
public sale in accordance with the method of disposition specified in such notice, the number of shares of Registrable Securities specified in such notice. 

  
 3 

 (b) Following receipt of any notice under Section 3.1(a), the Company shall immediately
notify all holders of Registrable Securities from whom notice has not been received and such holders shall then be entitled within thirty (30) days after receipt of such notice from the Company to request the Company to include in the requested
registration all or any portion of their shares of Registrable Securities. The Company shall use its best efforts to register under the Securities Act, for public sale in accordance with the method of disposition specified in the notice from
requesting holders described in paragraph (a) above, the number of shares of Registrable Securities specified in such notice (and in all notices received by the Company from other holders within thirty (30) days after the receipt of such
notice by such holders). The Company shall be obligated to register the Registrable Securities pursuant to this Section 3.1 on one (1) occasion only, provided, however, that such obligation shall be deemed satisfied only when
a registration statement covering all shares of Registrable Securities specified in notices received as aforesaid (except to the extent reduced by the managing underwriter, if any, pursuant to Section 3.1(d)), for sale in accordance with the
method of disposition specified by the requesting holders, shall have become effective and, if such method of disposition is a firm commitment underwritten public offering, all such shares shall have been sold pursuant thereto. Notwithstanding
anything to the contrary contained herein, no request may be made under this Section 3.1 after the effective date of a registration statement filed by the Company covering a firm commitment underwritten public offering and prior to the later to
occur of the completion of the period of distribution for such offering or 180 days after the effective date of such registration statement. 
 (c) If the holders requesting such registration intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their
request made pursuant to this Section 3.1 and the Company shall include such information in the written notice referred to in paragraph (b) above. The right of any holder to registration pursuant to this Section 3.1 shall be
conditioned upon such holder’s agreeing to participate in such underwriting and to permit inclusion of such holder’s Registrable Securities in the underwriting. If such method of disposition is an underwritten public offering, the Company
may designate the managing underwriter of such offering. A holder may elect to include in such underwriting all or a part of the Registrable Securities it holds. 
 (d) A registration statement filed pursuant to this Section 3.1 may, subject to the following provisions, include (i) shares of Common Stock for sale by the Company for its own account,
(ii) shares of Common Stock held by officers or directors of the Company, and (iii) shares of Common Stock held by persons (“Other Stockholders”) having “piggyback” registration rights to have such shares of Common
Stock included in such registration, in each case for sale in accordance with the method of disposition specified by the requesting holders. If such registration shall be underwritten, the Company, such officers and directors and such Other
Stockholders proposing to distribute their shares through such underwriting shall enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for such underwriting on terms no less
favorable to such officers and directors and such Other Stockholders than the terms afforded the holders of Registrable Securities. If and to the extent that the managing underwriter determines that marketing factors require a limitation on the
number of shares to be included in such registration, then the shares of Common Stock held by officers or directors (other than Registrable Securities) of the Company and shares of Common Stock to be sold by the Company for its own account shall be
excluded 

  
 4 

 
from such registration to the extent so required by such managing underwriter, and, unless the holders of such shares and the Company have otherwise agreed in writing, such exclusion shall be
applied first to the shares held by the directors and officers to the extent required by the managing underwriter, then to the shares of Common Stock of the Company to be included for its own account to the extent required by the managing
underwriter. If the managing underwriter determines that marketing factors require a limitation of the number of Registrable Securities and shares of Common Stock held by Other Stockholders to be registered pursuant to this Section 3.1, then
the shares of Common Stock held by Other Stockholders shall be excluded (pro rata based upon their ownership of shares of Common Stock sought to be registered) before any portion of the Registrable Securities held by the Investor shall be excluded.
No Registrable Securities or any other security excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. If any holder of Registrable Securities, officer or director or Other
Stockholder who has requested inclusion in such registration as provided above, disapproves of the terms of the underwriting, such holder of securities may elect to withdraw therefrom by written notice to the Company and the managing underwriter.
The securities so withdrawn shall also be withdrawn from registration. 
 (e) The Company shall use its best efforts to qualify
for registration on Form S-3 or any comparable or successor form or forms; and to that end the Company shall register (whether or not required by law to do so) the Common Stock under the Exchange Act in accordance with the provisions of that Act
following the effective date of the first registration of any securities of the Company on Form S-1 or any comparable or successor form. 

3.2 Registration Procedures. If and whenever the Company is required by the provisions of Section 3.1 to use its best efforts to effect the
registration of any Registrable Securities under the Securities Act, the Company will, as expeditiously as possible: 
 (a)
prepare and file with the Commission a registration statement with respect to such securities including executing an undertaking to file post-effective amendments and use its best efforts to cause such registration statement to become and remain
effective for the period of the distribution contemplated thereby; 
 (b) prepare and file with the Commission such amendments
and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for the period specified herein and comply with the provisions of the Securities Act
with respect to the disposition of all Registrable Securities covered by such registration statement in accordance with the sellers’ intended method of disposition set forth in such registration statement for such period; 

(c) furnish to each seller of Registrable Securities and to each underwriter such number of copies of the registration statement and each
such amendment and supplement thereto (in each case including all exhibits) and the prospectus included therein (including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale or other
disposition of the Registrable Securities covered by such registration statement; 
 (d) use its best efforts to register or
qualify the Registrable Securities covered by such registration statement under the securities or “blue sky” laws of such jurisdictions as the sellers 

  
 5 

 
of Registrable Securities or, in the case of an underwritten public offering, the managing underwriter reasonably shall request, provided, however, that the Company shall not for any such
purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction, unless the Company is already subject to
service in such jurisdiction; 
 (e) use its best efforts to list the Registrable Securities covered by such registration
statement with any securities exchange on which the Common Stock of the Company is then listed; 
 (f) comply with all
applicable rules and regulations under the Securities Act and Exchange Act; 
 (g) immediately notify each seller of Registrable
Securities and each underwriter under such registration statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event of which the Company has knowledge as a result of
which the prospectus contained in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not
misleading in light of the circumstances then existing, and promptly prepare and furnish to such seller a reasonable number of copies of a prospectus supplemented or amended so that, as thereafter delivered to the purchasers of such Registrable
Securities, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then
existing; 
 (h) if the offering is underwritten and at the request of any seller of Registrable Securities, use its best
efforts to furnish on the date that Registrable Securities are delivered to the underwriters for sale pursuant to such registration: (i) an opinion dated such date of counsel representing the Company for the purposes of such registration,
addressed to the underwriters to such effects as reasonably may be requested by counsel for the underwriters, and (ii) a letter dated such date from the independent public accountants retained by the Company, addressed to the underwriters
stating that they are independent public accountants within the meaning of the Securities Act and that, in the opinion of such accountants, the financial statements of the Company included in the registration statement or the prospectus, or any
amendment or supplement thereof, comply as to form in all material respects with the applicable accounting requirements of the Securities Act, and such letter shall additionally cover such other financial matters (including information as to the
period ending no more than five (5) business days prior to the date of such letter) with respect to such registration as such underwriters reasonably may request; 
 (i) make available for inspection by each seller of Registrable Securities, any underwriter participating in any distribution pursuant to such registration statement, and any attorney, accountant or other
agent retained by such seller or underwriter, reasonable access to all financial and other records, pertinent corporate documents and properties of the Company, as such parties may reasonably request, and cause the Company’s officers, directors
and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration statement; and 

  
 6 

 (j) cooperate with the selling holders of Registrable Securities and the managing
underwriter, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold, such certificates to be in such denominations and registered in such names as such holders or the managing
underwriter may request at least two business days prior to any sale of Registrable Securities. 
 For purposes of this
Agreement, the period of distribution of Registrable Securities in a firm commitment underwritten public offering shall be deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of
distribution of Registrable Securities in any other registration shall be deemed to extend until the earlier of the sale of all Registrable Securities covered thereby or 180 days after the effective date. 

In connection with each registration hereunder, the sellers of Registrable Securities will furnish to the Company in writing such
information requested by the Company with respect to themselves and the proposed distribution by them as shall be reasonably necessary in order to assure compliance with Federal and applicable state securities laws. 

3.3 Expenses. 

(a) All expenses incurred by the Company in complying with Sections 3.1 and 3.2, including, without limitation, all registration and
filing fees, printing expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or “blue sky”
laws, fees of the National Association of Securities Dealers, Inc., transfer taxes, fees of transfer agents and registrars, costs of any insurance which might be obtained by the Company with respect to the offering by the Company, and fees and
disbursements of one counsel selected by a majority in interest of the sellers of Registrable Securities, but excluding any Selling Expenses, are called “Registration Expenses”. All underwriting discounts and selling commissions applicable
to the sale of Registrable Securities are called “Selling Expenses”. 
 (b) The Company will pay all Registration
Expenses in connection with any registration statement under Section 3.1; provided, that, in the event of a registration which is withdrawn at the request of the participating sellers other than as a result of the Company’s failure
to perform its obligations hereunder and other than as a result of a cutback by the underwriter of such registration in the amount of Registrable Securities which may be included in such registration, the participating sellers shall pay the
Registration Expenses with respect to such registration. All Selling Expenses in connection with any registration statement under 3.1 shall be borne by the participating sellers in proportion to the number of shares registered by each, or by such
participating sellers other than the Company (except to the extent the Company shall be a seller) as they may agree. 
 3.4 Indemnification
and Contribution. 
 (a) In the event of a registration of any of the Registrable Securities under the Securities Act
pursuant to Section 3.1, the Company will indemnify and hold harmless each holder of Registrable Securities, its officers, directors and partners, each underwriter of such Registrable Securities thereunder and each other person, if any, who
controls such holder or 

  
 7 

 
underwriter within the meaning of the Securities Act, against any expenses, losses, claims, damages or liabilities, joint or several, to which such holder, officer, director, partner, underwriter
or controlling person may become subject under the Securities Act or otherwise, insofar as such expenses, losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged
untrue statement of any material fact contained in any prospectus, offering circular or other document incident to such registration (including any related notification, registration statement under which such Registrable Securities were registered
under the Securities Act pursuant to Section 3.1, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof), (ii) any blue sky application or other document executed by the Company
specifically for that purpose or based upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws thereof (any such application,
document or information herein called a “Blue Sky Application”), (iii) any omission or alleged omission to state in any such registration statement, prospectus, amendment or supplement or in any Blue Sky Applications executed or filed
by the Company, a material fact required to be stated therein or necessary to make the statements therein not misleading, (iv) any violation by the Company or its agents of the Securities Act or any rule or regulation promulgated under the
Securities Act applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration, or (v) any failure to register or qualify the Registrable Securities in any state where the
Company or its agents has affirmatively undertaken or agreed in writing that the Company (the undertaking of any underwriter chosen by the Company being attributed to the Company) will undertake such registration or qualification (provided that in
such instance the Company shall not be so liable if it has used its best efforts to so register or qualify the Registrable Securities) and will reimburse each such seller, and such officer, director and partner, each such underwriter and each such
controlling person for any legal or other expenses reasonably incurred by them in connection with investigating, preparing or defending any such expense, loss, claim, damage, liability or action, promptly after being so incurred, provided,
however, that the Company will not be liable in any such case if and to the extent that any such expense, loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged
omission so made in conformity with written information furnished by any such holder, any such underwriter or any such controlling person in writing specifically for use in such registration statement or prospectus. 

(b) In the event of a registration o f any of the Registrable Securities under the Securities Act pursuant to Section 3.1, each
seller of such Registrable Securities thereunder, severally and not jointly, will indemnify and hold harmless the Company, each person, if any, who controls the Company within the meaning of the Securities Act, each officer of the Company who signs
the registration statement, each director of the Company, each other seller of Registrable Securities, each underwriter and each person who controls any underwriter within the meaning of the Securities Act, against all expenses, losses, claims,
damages or liabilities, joint or several, to which the Company or such officer, director, other seller, underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such expenses, losses, claims, damages or
liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in any prospectus offering circular or other document incident to such registration (including
any related notification, registration statement under which such Registrable Securities were 

  
 8 

 
registered under the Securities Act pursuant to Section 3.1, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof), or any Blue Sky
Application or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and each such
officer, director, other seller, underwriter and controlling person for any legal or other expenses reasonably incurred by them in connection with investigating, preparing or defending any such expense, loss, claim, damage, liability or action,
promptly after being so incurred, provided, however, that such seller will be liable hereunder in any such case if and only to the extent that any such expense, loss, claim, damage or liability arises out of or is based upon an untrue
statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information pertaining to such seller, as such, furnished in writing to the Company by such seller specifically for use in such
registration statement or prospectus; and provided, further, however, that the liability of each seller hereunder shall be limited to the proportion of any such expense, loss, claim, damage, liability or expense which is equal
to the proportion that the public offering price of the securities sold by such seller under such registration statement bears to the total public offering price of all securities sold thereunder, but not in any event to exceed the proceeds received
by such seller from the sale of Registrable Securities covered by such registration statement. Not in limitation of the foregoing, it is understood and agreed that the indemnification obligations of any seller hereunder pursuant to any underwriting
agreement entered into in connection herewith shall be limited to the obligations contained in this subparagraph (b). 
 (c)
Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party
in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have to such indemnified party other than under this Section 3.4 and shall only relieve it from any liability which it
may have to such indemnified party under this Section 3.4 if and to the extent the indemnifying party is prejudiced by such omission. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying
party of the commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel satisfactory to such indemnified party, and, after notice from
the indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 3.4 for any legal expenses subsequently
incurred by such indemnified party m connection with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected, provided, however, that, if the defendants in any such action include both
the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party or
that the interests of the indemnified party reasonably may be deemed to conflict with the interests of the indemnifying party, the indemnified party shall have the right to select a separate counsel and to assume such legal defenses and otherwise to
participate in the defense of such action, with the expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the indemnifying party as incurred. No indemnifying party, in the defense of any such
claim or action, shall, except with the consent of each indemnified party, 

  
 9 

 
consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a
release from all liability in respect to such claim or action. Each indemnified party shall furnish such information regarding itself or the claim in question as an indemnifying party may reasonably request in writing and as shall be reasonably
required in connection with defense of such claim and litigation resulting therefrom. 
 (d) In order to provide for just and
equitable contribution to joint liability under the Securities Act in any case in which either (i) any holder of Registrable Securities exercising rights under this Agreement, or any controlling person of any such holder, makes a claim for
indemnification pursuant to this Section 3.4 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that
such indemnification may not be enforced in such case notwithstanding the fact that this Section 3.4 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any such selling
holder or any such controlling person in circumstances for which indemnification is provided under this Section 3.4; then, and in each such case, the Company and such holder will contribute to the aggregate expenses, losses, claims, damages or
liabilities to which they may be subject (after contribution from others) in such proportion so that such holder is responsible for the portion represented by the percentage that the public offering price of its Registrable Securities offered by the
registration statement bears to the public offering price of all securities offered by such registration statement, and the Company is responsible for the remaining portion; provided, however, that, in any such case, (A) no such
holder of Registrable Securities will be required to contribute any amount in excess of the proceeds received from the sale of all such Registrable Securities offered by it pursuant to such registration statement; and (B) no person or entity
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation. 

(e) The indemnities and obligations provided in this Section 3.4 shall survive the transfer of any Registrable Securities by such
holder. 
 3.5 Changes in Common Stock. If, and as often as, there is any change in the Common Stock by way of a stock split, stock
dividend, combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby
shall continue with respect to the Common Stock as so changed. 
 3.6 Rule 144 Reporting. With a view to making available the benefits of
certain rules and regulations of the Commission which may at any time permit the sale of the Registrable Securities to the public without registration, except as provided in paragraph (c) below, at all times after ninety (90) days after
any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, the Company agrees to: 
 (a) make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act (or any successor rule); 

  
 10 

 (b) use its best efforts to file with the Commission in a timely manner all reports and
other documents required of the Company under the Securities Act and the Exchange Act; and 
 (c) furnish to each holder of
Registrable Securities forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of such Rule 144 (or any successor rule) and, at any time after it has become subject to such reporting
requirements, of the Securities Act and the Exchange Act, a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so filed by the Company as such holder may reasonably request in availing itself of
any rule or regulation of the Commission allowing such holder to sell any Registrable Securities without registration. 
 3.7 “Market
Stand-Off” Agreement. The Investor agrees, if requested by the Company and an underwriter of Common Stock (or other securities) of the Company, not to sell or otherwise transfer or dispose of any Common Stock (or other securities) of the
Company held by such Investor during a period not to exceed one hundred and eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act, and to enter into an agreement to such effect;
provided that (y) all persons including Shares in such offering and (z) all of the Company’s officers, directors and holders of at least 5% of the outstanding Common Stock (or securities convertible into at least 5% of the
Common Stock) also enter into agreements to such effect. 
 The Company may impose stop-transfer instructions with respect to
the shares (or securities) subject to the foregoing restriction until the end of said period. 
 3.8 Assignment of Registration Rights.
The rights to cause the Company to register Registrable Securities pursuant to this Section 3 may be assigned (but only with all related obligations) by a holder of Registrable Securities to a transferee or assignee of such securities who is
not engaged in a business activity competitive with the Company (as reasonably determined by the Company’s Board of Directors) and who, after such assignment or transfer, holds at least 50,000 shares of Registrable Securities (subject to
appropriate adjustment for stock splits, stock dividends, combinations and similar recapitalization events), provided the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such
transferee or assignee and the securities with respect to which such registration rights are being assigned; and provided, further, that such assignment shall be effective only if (i) immediately following such transfer the further disposition
of such securities by the transferee or assignee is restricted under the Act and (ii) the transferee or assignee shall acknowledge in writing that the transferred or assigned Registrable Securities shall remain subject to this Agreement. For
the purposes of determining the number of shares of Registrable Securities held by a transferee or assignee, the holdings of transferees and assignees of a partnership who are partners or retired partners of such partnership (including spouses and
ancestors, lineal descendants and siblings of such partners or spouses who acquire Registrable Securities by gift, will or intestate succession) shall be aggregated together and with the partnership; provided that all assignees and transferees who
would not qualify individually for assignment of registration rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any action under this Section 3. 

  
 11 

	4.	MISCELLANEOUS 

 4.1 Notices. All
notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party’s address set forth below or to such other address as a party may designate by notice hereunder, and shall be either
(i) delivered by hand, (ii) made by telecopy or facsimile transmission, (iii) sent by overnight courier, or (iv) sent by registered or certified mail, return receipt requested, postage prepaid. 

 

			
	If to the Company:	    	Paratek Pharmaceuticals, Inc.
		    	75 Kneeland Street
		    	Room 1526
		    	Boston, MA 021111
		    	Attn: George C. Hillman, COO
		    	Facsimile: (617) 636-6912
		
	With a copy to:	    	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
		    	One Financial Center
		    	Boston, MA 02111
		    	Attn: Lewis J. Geffen, Esq.
		    	Facsimile: (617) 542-2241
		
	If to the Investor:	    	Glaxo Group Limited
		    	Glaxo Wellcome House
		    	Greenford
		    	Middlesex UB6 ONN
		    	UK
		    	Attn: Company Secretary
		    	Facsimile: 44 181 966 8679

 All notices, requests, consents and other communications hereunder shall be deemed to have been given
either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by telecopy or facsimile transmission, at the time that receipt thereof has been acknowledged by
electronic confirmation or otherwise, (iii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the fifth business
day following the day such mailing is made. 
 4.2 Entire Agreement. This Agreement embodies the entire agreement and understanding
between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any
kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 
 4.3 Modifications and Amendments. This Agreement may not be amended or modified, and no provision hereof may be waived, without the written consent of the Company and the holders of at least fifty
percent (50 %) of the outstanding shares of Series B Preferred Stock. Any waiver or consent hereunder shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or
consent. 

  
 12 

 4.4 Assignment. The rights and obligations under this Agreement may not be assigned by the Company
without the prior written consent of at least a majority of the holders of Registrable Securities, unless specifically permitted by the terms hereof. 
 4.5 Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective
successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this
Agreement. 
 4.6 Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance
with and governed by the law of the Commonwealth of Massachusetts, without giving effect to the conflict of law principles thereof. 
 4.7
Jurisdiction and Service of Process. Any legal action or proceeding with respect to this Agreement shall be brought in the courts of the Commonwealth of Massachusetts or of the United States of America for the District of Massachusetts. By
execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts. Each of the parties hereto irrevocably consents to the
service of process of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by certified mail, postage prepaid, to the party at its address set forth in Section 4.1 hereof. 

4.8 Severability. In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in
this Agreement shall be unenforceable in any respect, then such provision shall be deemed limited to the extent that such court deems it enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem
any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect. 
 4.9 Interpretation. The parties heres acknowledge and agree that: (i) each party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its
revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be
construed fairly as to all parties hereto and not in favor of or against any party, regardless of which party was generally responsible for the preparation of this Agreement. 
 4.10 Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify or affect the meaning or
construction of any of the terms or provisions hereof. 
 4.11 Enforcement. Each of the parties hereto acknowledges and agrees that the
rights acquired by each party hereunder are unique and that irreparable damage would occur in the event that any of the provisions of this Agreement to be performed by the other parties were not

  
 13 

 
performed in accordance with their specific terms or were otherwise breached. Accordingly, in addition to any other remedy to which the parties hereto are entitled at law or in equity, each party
hereto shall be entitled to an injunction or injunctions to prevent breaches of this Agreement by any other party and to enforce specifically the terms and provisions hereof in any federal or state court to which the parties have agreed hereunder to
submit to jurisdiction. 
 4.12 No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right,
power or remedy under this Agreement, and no course of dealing among the parties hereto, shall operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this Agreement by a
party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election
of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice
or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.

 4.13 Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

  
 14 

 IN WITNESS WHEREOF, the parties hereto have executed this Investor Rights Agreement
or caused this Agreement to be executed by their duly authorized representatives, as of the date first written above. 
  

					
	PARATEK PHARMACEUTICALS, INC.
		
	BY:	 	 /s/ George Hillman

		 	Name:	 	George C. Hillman
		 	Title:	 	Executive Vice President and
		 		 	Chief Operating Officer
	
	GLAXO GROUP LIMITED
		
	By:	 	 /s/ James Niedel

	Name: James E. Niedel
	Title: Executive Director

  
 15Third Amended and Restated Investor Rights Agreement

 Exhibit 4.4 
 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 THIS THIRD AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of October 19, 2007, by and among (i) Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), (ii) all holders of
the Company’s common stock listed on Exhibit A (referred to herein individually as a “Founder” and collectively as the “Founders”), (iii) the Series C Investors listed on Exhibit B (the
“Series C Investors”), (iv) the Series D Investors listed on Exhibit C (the “Series D Investors”), (v) the Series F Investors listed on Exhibit D (the “Series F Investors”)
and (vi) the Series H Investors listed on Exhibit E (the “Series H Investors,” together with the Series C Investors, Series D Investors and Series F Investors, the “Investors”). The Founders and the
Investors may be referred to herein individually as a “Stockholder,” and collectively as “Stockholders.” This Agreement amends and restates the Investor Rights Agreement dated as of April 28, 2000, as such
Investor Rights Agreement was amended and restated as of September 20, 2001 and June 2, 2004, respectively. 

WHEREAS, the Company, the Founders, the Series C Investors, the Series D Investors and the Series F Investors are each party to that
certain Second Amended and Restated Investor Rights Agreement, dated June 2, 2004 (the “Second Amended and Restated IRA”) in connection with the issuance by the Company (a) to the Series C Investors of 5,100,500 shares of
the Company’s Series C Convertible Preferred Stock, $.001 par value per share, convertible into shares of the Company’s common stock, $.001 par value per share (the “Series C Stock”), (b) to the Series D Investors of
6,390,866 shares of the Company’s Series D Convertible Preferred Stock, par value $.001 per share, convertible into shares of the Company’s common stock, $.001 par value per share (the “Series D Stock”) and (c) to the
Series F Investors of 925,412 shares of the Company’s Series F Convertible Preferred Stock, par value $.001 per share, convertible into shares of the Company’s common stock, $.001 par value per share (the “Series F Stock”)
and warrants to purchase an additional 441,826 shares of Series F Stock (the “Warrant Shares”); 
 WHEREAS, the
Series H Investors have purchased shares (the “Series H Stock”) of the Company’s Series H Convertible Preferred Stock, $.001 par value per share, convertible into shares of the Company’s common stock, $.001 par value per
share, pursuant to the terms of that certain Securities Purchase Agreement, dated October 10, 2007, by and among the Series H Investors and the Company (the “Securities Purchase Agreement”) (the Series C Stock, Series D Stock,
Series F Stock and the Series H Stock may be referred to herein collectively as the “Investor Preferred Stock”); 
 WHEREAS, Series C Investors, Series D Investors and Series F Investors party hereto, holding in the aggregate a sufficient number of shares of Series C Stock, Series D Stock and Series F Stock necessary
to amend the Second Amended and Restated IRA in accordance with the provisions of Section 8.3 thereof, desire, as hereinafter provided, to amend and restate the Second Amended and Restated IRA in order to add the Series H Investors as parties
thereto; and 
 WHEREAS, the Board of Directors of the Company has determined that it is in the best interests of the Company
that the Company enter into this Agreement. 

 NOW, THEREFORE, in consideration of the covenants and agreements set forth herein and for
other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties hereto covenant and agree as follows: 
  

	1.	GENERAL PROVISIONS 

 1.1 Amendment and
Restatement of Second Amended and Restated IRA. The Second Amended and Restated IRA is hereby amended and restated and superceded and replaced in its entirety by this Agreement. 
 1.2 Shares Subject to this Agreement. The Stockholders expressly agree that the terms and restrictions of this Agreement shall apply to all shares of the Company’s capital stock which any of
them now owns or hereafter acquires by any means, including, without limitation, by purchase, assignment or operation of law, or as a result of any stock dividend, stock split, reorganization, reclassification, whether voluntary or involuntary, or
other similar transaction, and to any shares of capital stock of any successor in interest of the Company, whether by sale, merger, consolidation or other similar transaction, or by purchase, assignment or operation of law (the
“Shares”). 
 1.3 No Partnership Relationship. Notwithstanding, but not in limitation of, any other provision of this
Agreement, the parties understand and agree that the creation, management and operation of the Company shall not create or imply a general partnership between or among the Investors and shall not make any Investor the agent or partner of any other
Investor for any purpose. 
 1.4 Certain Definitions. As used in this Agreement, the following terms shall have the following respective
meanings: 
 “Affiliate” has the meaning ascribed to that term in Rule 12b-2 under the Exchange Act, or any
successor rule. 
 “Commission” shall mean the United States Securities and Exchange Commission and any
successor agency of the Federal government administering the Securities Act and the Exchange Act. 
 “Common
Stock” shall mean (i) the common stock, par value $.001 per share, of the Company, (ii) any other capital stock of the Company, however designated, authorized on or after the date hereof, which shall neither be limited to a fixed
sum or percentage of par value in respect of the rights of the holders thereof to participate in dividends nor entitled to a preference in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of the
Company, and (iii) any other securities into which or for which any of the securities described in (i) or (ii) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, consolidation, sale of assets
or other similar transaction. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and
any similar or successor Federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect from time to time. 

  
 2 

 “Initial Public Offering” shall mean the first underwritten public offering
of Common Stock of the Company at a price per share no less than $6.14 (subject to appropriate adjustment for stock splits, reverse stock splits, stock dividends, combinations and other similar recapitalization events), offered on a firm commitment
basis pursuant to a registration statement filed with the Commission under the Securities Act on Form S-1 or its then equivalent, in which the aggregate gross proceeds to the Company equals or exceeds $40,000,000. 

“Person” means an individual, corporation, partnership, joint venture, trust or unincorporated organization, or a
government or any agency or political subdivision thereof. 
 The terms “register”,
“registered” and “registration” shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the
declaration or ordering of the effectiveness of such registration statement under the Securities Act, or, as the context may require, under the Exchange Act or applicable state securities laws. 

“Registrable Securities” shall mean (i) shares of Common Stock or other securities issued or issuable pursuant to
the conversion of the Investor Preferred Stock (including the Warrant Shares); and (ii) any shares of Common Stock or other securities issued or issuable pursuant to the conversion of the Investor Preferred Stock upon any stock split, stock
dividend, recapitalization, reorganization, merger, consolidation, sale of assets or similar event, excluding in any event securities which have been (a) registered under the Securities Act pursuant to an effective registration statement filed
thereunder and disposed of in accordance with the registration statement covering them or (b) publicly sold pursuant to Rule 144 under the Securities Act; provided that, with respect to any holder (other than Persons who are
Affiliates of the Company), shares of Common Stock or other securities held by such holder shall cease to be Registrable Securities at such time when such holder can sell such shares of Common Stock or other securities pursuant to Rule 144(k) under
the Securities Act. Wherever reference is made in this Agreement to a request or consent of holders of a certain percentage of Registrable Securities, the determination of such percentage shall be calculated on the basis of shares of Common Stock
issued or issuable upon conversion of the Investor Preferred Stock even if such conversion has not been effected. 

“Registration Expenses” shall mean the expenses so described in Section 4.7(a). 

“Securities Act” shall mean the Securities Act of 1933, as amended, and any similar or successor Federal statute, and
the rules and regulations of the Commission thereunder, all as the same shall be in effect from time to time. 

“Selling Expenses” shall mean the expenses so described in Section 4.7(a). 

“Series H Original Issue Date” shall mean the date on which shares of Series H Stock were first issued. 

“Subsidiary” or “Subsidiaries” shall mean any corporation, partnership, trust or other entity of
which the Company and/or any of its other Subsidiaries directly or indirectly owns at the time a majority of the outstanding shares of any class of equity security of such corporation, partnership, trust or other entity. 

  
 3 

	2.	PREEMPTIVE RIGHTS 

 2.1 Notice of New
Issuance. Except with respect to “Exempt Issuances” as defined in Section 2.3, in the event that the Company plans to issue any (i) shares of Common Stock, (ii) warrants, options or other rights to purchase Common Stock
(collectively, “Rights”), or (iii) any debentures or other securities (including capital stock) convertible into or exchangeable for shares of Common Stock (collectively, “Convertible Securities”), the Company
will deliver to the Investors a notice (the “Offer Notice”), promptly upon the completion of such issuance (the “New Issuance”), stating the price and other terms and conditions thereof. 

2.2 Right to Purchase Shares, Rights or Convertible Securities. In the event of a New Issuance (other than an Exempt Issuance), the Investors
shall have the right to purchase such number of shares of Common Stock, Rights or Convertible Securities at the price and on the terms upon which such New Issuance was made, such that, after giving effect to the issuance to the Investors and the
conversion, exercise and exchange into or for (whether directly or indirectly) shares of Common Stock of all such Rights and Convertible Securities, each Investor who exercises such right will continue to maintain his, her or its same proportionate
ownership of Common Stock as of the date immediately preceding the New Issuance, treating each Investor, for the purpose of such computation, as the holder of the number of shares of Common Stock which would be issuable to him, her or it, as the
case may be, upon conversion, exercise and exchange of all Rights and Convertible Securities held by him, her or it on the date immediately preceding the New Issuance and assuming the like conversion, exercise and exchange of all such securities
held by other Persons. The rights set forth in this Article 2 shall be exercised by the Investors, if at all, by written notice to the Company delivered not later than thirty (30) days after the receipt by the Investors of the Offer Notice in
accordance with the terms and conditions stated therein and such right shall expire at the end of the thirtieth day after the day of the receipt by the Investors of the Offer Notice. 
 2.3 Exempt Issuances. The issuances referred to in Section 2.1 which will not give the Investors the rights described in Section 2.2 (the “Exempt Issuances”) are
issuances in which shares of Common Stock or Rights or Convertible Securities of the Company are issued or deemed issued (i) as a dividend or distribution payable pro rata to all holders of Common Stock or other securities of the Company;
(ii) in connection with Rights to purchase up to six million (6,000,000) shares of Common Stock (which amount shall be subject to equitable adjustment whenever there shall occur a stock dividend, stock split, combination of shares,
reclassification or other similar event with respect to the Common Stock) issued or issuable to employees, consultants, officers and directors of the Company pursuant to the Company’s 1996 Employee, Director and Consultant Stock Plan, 2005
Employee, Director and Consultant Stock Plan or any other equity plan or arrangement approved by the Company’s Board of Directors in accordance with Section 6.2(d) unless a higher number of Rights is approved by holders of at least fifty
percent (50%) of the Investor Preferred Stock, voting together as a single class on an as-converted basis; (iii) in connection with the exercise of any preemptive or percentage maintenance rights outstanding on the date hereof;
(iv) in connection with the conversion or exercise of any Rights or Convertible Securities outstanding on the date hereof; (v) in connection with an acquisition by the Company of stock or assets of another Person, provided that the Company
acquires at least fifty percent (50%) of the voting power of the other Person, and the acquisition has been approved in accordance with Section 6.2(f); (vi) in connection with 

  
 4 

 
commercial or equipment financing not to exceed an amount equal to four percent (4%) of the fully-diluted equity of the Company immediately after the final closing of the Series H Stock
transaction; or (vii) in connection with the Company’s Initial Public Offering. 
 2.4 Termination. The respective rights and
obligations of the parties under this Article 2 shall terminate upon to the consummation of the Company’s Initial Public Offering. 
  

	3.	RESTRICTIONS ON TRANSFER; INVESTOR PARTICIPATION IN SALES 

 3.1 Restrictions on Transfer by Stockholders. The Stockholders hereby agree to the provisions set forth in this Article 3 with respect to any sale, transfer or other disposition of Shares, in the
event such sale, transfer or disposition is allowed pursuant to Section 4.2 hereof. 
 3.2 Non-Complying Transfers Prohibited. Each
Stockholder understands that he may not sell, assign, transfer, exchange, gift, devise, pledge, hypothecate, encumber or otherwise alienate or dispose of any Shares, or any right or interest therein, whether voluntarily or involuntarily, by
operation of law or otherwise, except in accordance with this Agreement. Any such purported transfer in violation of any provision of this Agreement and all actions by the purported transferor and transferee in connection therewith shall be of no
force or effect. The Company shall not recognize such purported transfer for any purpose, including, without limitation, for the purposes of dividend and voting rights. If any transfer of Shares is made or attempted contrary to the provisions of
this Agreement or if any Shares are not offered as required by this Agreement, the Company or the other holders of Shares of the Company shall have the right to purchase such Shares from each such transferring Stockholder or each such transferee at
any time before or after each such purported transfer, as hereinafter provided. In addition to any other legal or equitable remedies the Company or such other holders may have, the Company and such other holders may enforce this right by actions for
specific performance, to the extent permitted by law. 
 3.3 Rights of First Refusal on Voluntary Transfers. 

(a) Right of First Refusal of the Company. Except as otherwise provided herein, any Stockholder who intends to sell, assign,
transfer or otherwise voluntarily alienate or dispose of any Shares in one transaction or a series of related transactions (the “Selling Stockholder”) shall, prior to any such transfer, give written notice (the “Selling
Stockholder’s Notice”) of such intention to the Company and to the Investors. The Selling Stockholder’s Notice shall include the name of the proposed transferee, the proposed purchase price per Share, the terms of payment of such
purchase price and all other matters relating to such sale and shall be accompanied by a copy of a binding written agreement of the proposed transferee to purchase such Shares from the Selling Stockholder. The Selling Stockholder’s Notice shall
constitute a binding offer by the Selling Stockholder to sell to the Company or its designee all or any part of such number of Shares (the “Offered Shares”) then owned by the Selling Stockholder as are proposed to be sold in the
Selling Stockholder’s Notice at the monetary price per Share designated in the Selling Stockholder’s Notice, payable as provided in Section 3.3(c). Not later than twenty (20) days after receipt of the Selling Stockholder’s
Notice, the Company shall deliver written notice to the Selling Stockholder stating whether the Company has accepted the offer stated in the Selling Stockholder’s Notice (in whole or in part); provided, however, that the

  
 5 

 
Company shall not accept such offer without the prior approval of Company’s Board of Directors (including each of the Series H Directors (as hereinafter defined)). The closing of any
purchase of the Offered Shares by the Company shall take place on the later of (i) fifteen (15) days after the end of the twenty (20) day period set forth above and (ii) the date on which the Investors consummate any purchase of
Offered Shares pursuant to Section 3.3(b) below. Notwithstanding anything to the contrary contained herein, the Company may accept the offer stated in the Selling Stockholder’s Notice without the prior approval of the Company’s Board
of Directors as required by this Section 3.3(a) in the event that the Company has not purchased in excess of fifty thousand (50,000) Shares pursuant to this Section 3.3(a) (subject to appropriate adjustment for stock splits, stock
dividends, combinations and similar recapitalization events) during any twelve (12) month period. 
 (b) Right of First
Refusal of the Investors. If the Company does not accept the offer to purchase all of the Offered Shares within the twenty (20) day period provided in Section 3.3(a), no later than the end of such twenty (20) day period the
Company shall give notice (the “Company Notice”) of that fact to each Investor and each Investor shall have the right to purchase all or any part of its Proportionate Percentage (as defined below) of the Offered Shares not purchased
by the Company or its designee (the “Remaining Shares”), at the monetary price per Share designated in the Selling Stockholder’s Notice, payable as provided in Section 3.3(c). Not later than fifteen (15) days after
delivery of the Company Notice, each Investor shall deliver to the Company, the other Investors and the Selling Stockholder a written notice stating whether such Investor has accepted the offer stated in the Selling Stockholder’s Notice with
respect to its Proportionate Percentage of the Remaining Shares. If one (1) or more of the Investors elects not to purchase all of the Remaining Shares which it is entitled to purchase pursuant to this Section 3.3(b), the other Investors,
by written notice to the Company and the Selling Stockholder within five (5) days after the end of the fifteen (15) day period set forth above, may elect to purchase all or a part of such unpurchased Remaining Shares without the consent of
any non-purchasing Investors, pro rata between or among them or in such other manner as they may agree. The closing of any purchase of the Remaining Shares by the Investors shall take place no later than fifteen (15) days after the end of the
fifteen (15) day period set forth above. As used in this Section 3.3(b), “Proportionate Percentage” shall mean with respect to each Investor a fraction, the numerator of which is the number of Shares owned by such Investor
(calculated on a fully diluted basis), and the denominator of which is the total number of Shares owned by all Investors (calculated on a fully diluted basis). 
 (c) Closing. The place for the closing of any purchase and sale described in Section 3.3(a) or Section 3.3(b) shall be the principal office of the Company or at such other place as the
parties shall agree. At the closing, the Selling Stockholder shall accept payment on the terms (including price) offered by the proposed transferee named in the Selling Stockholder’s Notice, provided, however, that the Company and
the Investors shall not be required to meet any non-monetary terms of the proposed transfer, including, without limitation, delivery of consideration in the form of other securities in exchange for the Shares proposed to be sold. At the closing, the
Selling Stockholder shall deliver to the Company or the Investors, as the case may be, in exchange for Shares purchased and sold at the closing, certificates for the number of Shares stated in the Selling Stockholder’s Notice, accompanied by
duly executed instruments of transfer. 

  
 6 

 (d) Transfers to Third Parties. If the Company and the Investors in the aggregate
fail to accept the offer stated in the Selling Stockholder’s Notice with respect to all of the Offered Shares, then the Selling Stockholder shall be free to sell any of the remaining shares of the Offered Shares not purchased by the Company and
the Investors at a price and on terms no less favorable to the Selling Stockholder than described in the Selling Stockholder’s Notice, provided, however, that such sale is consummated within ninety (90) days after the giving
of the Selling Stockholder’s Notice pursuant to Section 3.3(a). As a condition precedent to the effectiveness of a transfer pursuant to this Section 3.3(d), the proposed transferee(s) shall agree in writing prior to such transfer to
become a party to this Agreement and shall thereafter be permitted to transfer Shares only in accordance with this Agreement. 
 3.4
Participation in Sales. 
 (a) Take-Along Right. In the event that a Stockholder (the
“Offeree”) receives a bona fide offer from a third party or parties, other than from a Permitted Transferee (as defined below) or any other Stockholder (the “Offeror”), to acquire any of his, her or its Shares (the
“Take-Along Shares”) for a specified price payable in cash or otherwise and on specified terms and conditions (the “Offer”), and the Offeree proposes to sell or otherwise transfer the Take-Along Shares to the
Offeror pursuant to the Offer, the Offeree shall not effect such sale or transfer unless each Investor is first given the right to sell to the Offeror, at the same price per Share and on the same terms and conditions as stated in the Offer, the same
proportion of shares of Common Stock (or shares of Investor Preferred Stock then convertible into such number of shares of Common Stock) then owned by such Investor, as the proportion that the number of the Take-Along Shares bears to the total
number of shares of Common Stock held by the Offeree and all Investors on the date of the Company Notice. 
 (b) Notices of
Offer and Intent to Participate. If an Investor wishes to participate in any sale pursuant to Section 3.4(a) it shall notify the Offeree in writing of such intention and the number of Shares it wishes to sell pursuant to this
Section 3.4(b) not later than fifteen (15) days after delivery of the Company Notice (as described in Section 3.3(b) above). If the Offeree does not receive such notice from an Investor within such fifteen (15) day period, the
Offeree shall be free to consummate the proposed transaction without any obligation to include such Investor’s Shares in such transaction. 
 (c) Sale of Take-Along Shares. The Offeree and each Investor who has provided timely notice in accordance with Section 3.4(b) above shall sell to the Offeror all, or at the option of the
Offeror, any part of the Shares proposed to be sold by them at not less than the price and upon other terms and conditions, if any, not more favorable to the Offeror than those stated in the Offer, provided, however, that any purchase
of less than all of such Shares by the Offeror shall be made from the Offeree and each such Investor pro rata based upon the relative amount of the Shares that the Offeree and such Investor is entitled to sell pursuant to Section 3.4.

 3.5 Drag Along Obligation. If at any time after the fourth anniversary of the Series H Original Issue Date, holders representing at
least sixty-six and two-thirds percent (66-2/3%) of the Investor Preferred Stock then outstanding (the “Selling Investors”) shall approve (a) a proposal from a Person for the transfer, directly or indirectly, of a majority of
the Company’s stock to such Person (a “Stock Sale”), (b) the merger or consolidation of the Company with or 

  
 7 

 
into another Person in which the Company’s stockholders will receive cash or securities of any other Person for their shares or (c) the sale by the Company or its Subsidiaries of all or
substantially all of their assets to a Person, in each of the above cases for a specified price payable in cash or otherwise and on specified terms and conditions (a “Sale Proposal”), then the Company shall deliver a written notice
(a “Required Sale Notice”) with respect to such Sale Proposal to each Stockholder stating that the Selling Investors have approved a Sale Proposal and proposes to effect the Sale Proposal and providing the identity of the Persons
involved in such Sale Proposal and the terms thereof. Each such Stockholder, upon receipt of a Required Sale Notice, shall be obligated, which obligation shall be enforceable by the Selling Investors and the Company, to participate in the
transaction (a “Required Sale”) contemplated by the Sale Proposal, and agrees as follows: 
 (a) if such
transaction requires stockholder approval, with respect to all Shares that such Stockholder owns or over which such Stockholder otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all Shares
in favor of, and adopt, such Sale Proposal (together with any related amendment to the Company’s Certificate of Incorporation required in order to implement such Sale Proposal) and to vote in opposition to any and all other proposals that could
reasonably be expected to delay or impair the ability of the Company to consummate such Sale Proposal; 
 (b) if such
transaction is a Stock Sale, to sell the same proportion of Shares beneficially held by such Stockholder as is being sold by the Selling Investors to the Person to whom the Selling Investors propose to sell their Shares on the same terms and
conditions as the Selling Investors; 
 (c) to execute and deliver all related documentation and take such other action in
support of the Sale Proposal as shall reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Section 3.5, including, without limitation, executing and delivering instruments of
conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and
encumbrances) and any similar or related documents; 
 (d) not to deposit, and to cause their Affiliates not to deposit, except
as provided in this Agreement, any Shares owned by such party or Affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by the acquiror in
connection with the Sale Proposal; and 
 (e) if the consideration to be paid in exchange for the Shares pursuant to this
Section 3.5 includes any securities and due receipt thereof by any Stockholder would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such
securities or (y) the provision to any Stockholder of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated
under the Securities Act, the Company may cause to be paid to any such Stockholder in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Stockholder, an amount in cash equal to the fair value (as determined in
good faith by the Company’s Board of Directors) of the securities which such Stockholder would otherwise receive as of the date of the issuance of such securities in exchange for the Shares. 

  
 8 

 Any Required Sale Notice may be rescinded by the Company upon the request of the Selling Investors by
delivering written notice thereof to all of the Stockholders. 
 3.6 Transfers to Permitted Transferees. The provisions contained in this
Article 3 shall not apply to (a) transfers by a Stockholder to an Affiliate of such Stockholder, (b) if such Stockholder is a corporation, transfers to the stockholders of such corporation pursuant to a duly declared dividend,
(c) transfers to any nominee of such Stockholder made solely for bona fide internal administrative purposes, (d) transfers by a Stockholder to such Stockholder’s spouse, children or other member of such Stockholder’s immediate
family, or to a trust for the benefit of such persons, (e) transfers by a Stockholder to the trustee or trustees of a trust revocable solely by such Stockholder, (f) transfers by a Stockholder to such Stockholder’s guardian or
conservator, (g) transfers by a Stockholder, in the event of such Stockholder’s death, to such Stockholder’s executor(s) or administrator(s) or to trustee(s) under such Stockholder’s will or (h) transfers of (1) an
aggregate of 770,000 shares of Series C Stock by Schweizerhall Holding AG to Omega Fund III, L.P., (2) an aggregate of 65,732 shares of Series F Stock by Schweizerhall Holding AG to Omega Fund III, L.P. and (3) warrants for the purchase of
an aggregate of 16,433 shares of Series F stock by Schweizerhall Holding AG to Omega Fund III, L.P. (collectively, “Permitted Transferees”); provided, however, that in any such event the Shares so transferred in the
hands of each such Permitted Transferee shall remain subject to the provisions of this Article 3, and each such Permitted Transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such transfer. 

3.7 Waiver. From time to time the Company and/or each of the Stockholders may waive their rights hereunder either generally or with respect to one
or more specified transfers which have been proposed, attempted or made. 
 3.8 Termination. The respective rights and obligations of the
parties under this Article 3 shall terminate upon the consummation of the Company’s Initial Public Offering or a merger, acquisition or other form of corporate reorganization in which outstanding shares of the Company are exchanged for
securities or other consideration issued, or caused to be issued, by the acquiring corporation or its subsidiary (other than a mere reincorporation transaction) and pursuant to which the holders of the outstanding voting securities of the Company
immediately prior to such consolidation, merger or other transaction fail to hold (in substantially the same percentages) equity securities representing a majority of the voting power of the Company or surviving entity immediately following such
consolidation, merger or other transaction (excluding voting securities of the acquiring corporation held by such holders prior to such transaction), or the sale of all or substantially all of the assets of the Company. 

  
 9 

	4.	TRANSFER OF REGISTRABLE SECURITIES; REGISTRATION 

 4.1 Restrictive Legend. Each certificate representing Registrable Securities shall, except as otherwise provided in this Section 4.1 or in Section 4.2, be stamped or otherwise imprinted
with a legend substantially in the following form (in addition to any legend required under applicable state securities laws): 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY OTHER SECURITIES
LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933 AND ANY OTHER APPLICABLE SECURITIES LAWS, UNLESS THE HOLDER SHALL HAVE OBTAINED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION
IS NOT REQUIRED OR THE TRANSFEREE IS AN AFFILIATE OF THE HOLDER; PROVIDED THAT THE CORPORATION SHALL NOT REQUIRE SUCH OPINION OF COUNSEL WITH RESPECT TO TRANSFERS MADE PURSUANT TO RULE 144 OR REGULATIONS UNDER THE SECURITIES ACT.” 

In addition to the foregoing, each certificate representing Registrable Shares held by a Founder shall also be stamped or otherwise imprinted with a
legend substantially in the following form: 
 “THE SHARES REPRESENTED HEREBY ARE ALSO SUBJECT TO RESTRICTIONS ON TRANSFER
CONTAINED IN A CERTAIN STOCK SUBSCRIPTION AND RIGHT OF FIRST REFUSAL AGREEMENT, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT COMPLIANCE WITH THE TERMS THEREOF. THE COMPANY WILL FURNISH A COPY OF THE FULL TEXT OF SUCH RESTRICTIONS TO
THE HOLDER OF THIS CERTIFICATE UPON WRITTEN REQUEST AND WITHOUT CHARGE.” 
 4.2 Notice of Proposed Transfer. Subject to the
provisions of Article 3, prior to any proposed sale, pledge, hypothecation or other transfer of any Registrable Securities (other than under the circumstances described in Section 4.3, 4.4 or 4.5), the holder thereof shall give written notice
to the Company of its intention to effect such sale, pledge, hypothecation or other transfer. Each such notice shall describe the manner of the proposed sale, pledge, hypothecation or other transfer and, if requested by the Company shall be
accompanied by either (i) an opinion of counsel reasonably satisfactory to the Company to the effect that the proposed sale, pledge, hypothecation or other transfer may be effected without registration under the Securities Act or (ii) a
“no action” letter from the Commission to the effect that the distribution of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the
holder of such stock shall be entitled to transfer such stock in accordance with the terms of its notice; provided, however, that no such opinion of counsel or “no-action” letter shall be required by the Company (A) for
a distribution to one or more partners of the transferor (in the case of a transferor that is a partnership) or to a stockholder (in the case of a transferor that is a corporation) in each case in respect of the beneficial interest of such partner
or stockholder, or to an affiliate of such transferor, or (B) in the case of a transfer made in accordance with the provisions of Rule 144 or Regulation S under 

  
 10 

 
the Securities Act, although such opinion of counsel may be required by an independent transfer agent of the Company after the Initial Public Offering. Each certificate for Registrable Securities
transferred as above provided shall bear the appropriate restrictive legend or legends, as the case may be, set forth in Section 4.1, except that such certificate shall not bear the first such legend if (i) such transfer is in accordance
with the provisions of Rule 144 (or any other rule permitting public sale without registration under the Securities Act) or (ii) the opinion of counsel or “no-action” letter referred to above is to the further effect that the
transferee and any subsequent transferee (other than an affiliate of the Company) would be entitled to transfer such securities in a public sale without registration under the Securities Act or that the first such legend is not required to establish
compliance with any provisions of the Securities Act. Notwithstanding any other provision hereof, the restrictions provided for in this Section 4.2 shall not apply to securities that are not required to bear the legends prescribed by
Section 4.1 in accordance with the provisions of that Section. 
 4.3 Required Registration. 

(a) At any time after the earlier of (i) 180 days after the effective date of the registration statement covering the first
underwritten public offering of Common Stock of the Company (an “IPO”) and (ii) the third anniversary of the Series H Original Issue Date, holders of at least forty percent (40%) of the Investor Preferred Stock (including
Common Stock issuable upon conversion thereof), together as a single class, on three occasions only may request the Company to register for sale under the Securities Act all or any portion of the shares of Registrable Securities held by such
requesting holder or holders for sale in the manner specified in such notice; provided, however, that in the event of any such request, the aggregate offering price of shares of Registrable Securities to be registered on any such
registration statement, net of underwriting discounts and commissions, is at least Five Million Dollars ($5,000,000). Notwithstanding anything to the contrary contained herein, the Company shall not be required to effect a registration pursuant to
this Section 4.3 during the period commencing sixty (60) days prior to the estimated filing date of, and ending on the date which is one hundred eighty (180) days after the closing date of, a registration statement filed by the
Company covering an underwritten public offering of the Common Stock under the Securities Act, provided the Company is actively employing in good faith reasonable efforts to cause such registration statement to become effective and such estimate of
the filing date is made in good faith. If the Company shall furnish to the holders of Registrable Securities a certificate signed by its President stating that in the good faith judgment of its Board of Directors it would be seriously detrimental to
the Company or its stockholders for a registration statement to be filed at such time, then the Company’s efforts to cause a registration statement to be filed shall be deferred for a period not to exceed four (4) months in any twelve
(12) month period, provided that in such event, if the Company does not effect a registration requested pursuant to this Section 4.3, such request shall not be counted for purposes of the limitations on registrations set forth above and in
Section 4.3(b). 
 (b) Following receipt of any notice under this Section 4.3, the Company shall immediately notify
all holders of Registrable Securities from whom notice has not been received and such holders shall then be entitled within thirty (30) days after receipt of such notice from the Company to request the Company to include in the requested
registration all or any portion of their shares of Registrable Securities. The Company shall use reasonable best efforts to register 

  
 11 

 
under the Securities Act, for public sale in accordance with the method of disposition specified in the notice from requesting holders described in paragraph (a) above, the number of shares
of Registrable Securities specified in such notice (and in all notices received by the Company from other holders within thirty (30) days after the receipt of such notice by such holders). The Company shall be obligated to register the
Registrable Securities pursuant to this Section 4.3 on three (3) occasions only if requested by holders of at least forty percent (40%) of the Investor Preferred Stock, including, in each case Common Stock issuable upon conversion
thereof, provided, further, that such obligation shall be deemed satisfied only when a registration statement covering all shares of Registrable Securities specified in notices received as aforesaid, for sale in accordance with the
method of disposition specified by the requesting holders, shall have become effective and, if such method of disposition is a firm commitment underwritten public offering, sixty-six and two-thirds percent (66-2/3%) or more of such shares shall have
been sold pursuant thereto. The Company shall not be obligated to register, pursuant to this Section 4.3, the Registrable Securities of any holder who fails to provide promptly to the Company such information as the Company may reasonably
request at any time to enable the Company to comply with any applicable law or regulation or to facilitate preparation of the registration statement. 
 (c) If the holders requesting such registration intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall (i) so advise the Company as a part of
their request made pursuant to this Section 4.3 and the Company shall include such information in the written notice referred to in paragraph (b) above and (ii) designate the managing underwriter of such offering, which managing
underwriter shall be reasonably acceptable to the Company. The right of any holder to registration pursuant to this Section 4.3 shall be conditioned upon such holder’s agreeing to participate in such underwriting and to permit inclusion of
such holder’s Registrable Securities in the underwriting. A holder may elect to include in such underwriting all or a part of the Registrable Securities it holds. 
 (d) A registration statement filed pursuant to this Section 4.3 may, subject to the following provisions, include (i) shares of Common Stock for sale by the Company for its own account,
(ii) shares of Common Stock held by officers or directors of the Company and (iii) shares of Common Stock held by persons entitled to include such shares in such registration pursuant to “incidental” or “piggyback”
registration rights granted to such persons in accordance with Section 4.14 (the “Other Shareholders”), in each case for sale in accordance with the method of disposition specified by the requesting holders. If such
registration shall be underwritten, the Company, such officers and directors and Other Shareholders proposing to distribute their shares through such underwriting shall enter into an underwriting agreement in customary form with the representative
of the underwriter or underwriters selected for such underwriting on terms no less favorable to such officers, directors or Other Shareholders than the terms afforded the holders of Registrable Securities. If and to the extent that the managing
underwriter determines that marketing factors require a limitation on the number of shares to be included in such registration, then the shares of Common Stock held by officers or directors or by Other Shareholders (other than Registrable
Securities) and shares of Common Stock to be sold by the Company for its own account shall be excluded from such registration to the extent so required by such managing underwriter, and unless the holders of such shares and the Company have
otherwise agreed in writing, such exclusion shall be applied first to the shares held by the directors and officers of the Company and the Other Shareholders to the extent 

  
 12 

 
required by the managing underwriter, then to the shares of Common Stock of the Company to be included for its own account to the extent required by the managing underwriter. If the managing
underwriter determines that marketing factors require a limitation of the number of Registrable Securities to be registered under this Section 4.3, then Registrable Securities shall be excluded in such manner that the securities to be sold
shall be allocated pro rata among the selling holders based on their ownership of Registrable Securities. If, in such event, the managing underwriter reduces the number of shares of Registrable Securities to be registered under this Section 4.3
to an amount which is less than fifty percent (50%) of the number of shares specified in notices received under this Section 4.3, then such registration shall not be counted for purposes of the limitations on registrations set forth in
Section 4.3(b). In any event, all securities to be sold other than Registrable Securities will be excluded prior to any exclusion of Registrable Securities. No Registrable Securities or any other security excluded from the underwriting by
reason of the underwriter’s marketing limitation shall be included in such registration. If any holder of Registrable Securities, officer, director or Other Shareholder who has requested inclusion in such registration as provided above,
disapproves of the terms of the underwriting, such holder of securities may elect to withdraw therefrom by written notice to the Company and the managing underwriter. The securities so withdrawn shall also be withdrawn from registration. 

4.4 Incidental Registration. Except for the IPO, if the Company at any time (other than pursuant to Section 4.3 or 4.5) proposes to register
any of its securities under the Securities Act for sale to the public, whether for its own account or for the account of other security holders or both (except with respect to registration statements on Forms S-4, S-8 or any successor to such forms
or another form not available for registering the Registrable Securities for sale to the public), each such time it will promptly give written notice to all holders of the Registrable Securities of its intention so to do. Upon the written request of
any such holder, received by the Company within thirty (30) days after the giving of any such notice by the Company, to register any or all of its Registrable Securities, the Company will use reasonable best efforts to cause the Registrable
Securities as to which registration shall have been so requested to be included in the securities to be covered by the registration statement proposed to be filed by the Company, all to the extent requisite to permit the sale or other disposition by
the holder (in accordance with its written request) of such Registrable Securities so registered. If the registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the
holders of Registrable Securities as a part of the written notice given pursuant to this Section 4.4. In such event the right of any holder of Registrable Securities to registration pursuant to this Section 4.4 shall be conditioned upon
such holder’s participation in such underwriting to the extent provided herein. All holders of Registrable Securities proposing to distribute their securities through such underwriting shall (together with the Company and the Other Shareholders
distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for underwriting by the Company. Notwithstanding any other provision of this
Section 4.4, if the managing underwriter determines that marketing factors require a limitation on the number of shares to be underwritten, the Company shall so advise all holders of securities requesting registration of any limitations on the
number of shares to be underwritten, and the number of shares of securities that are entitled to be included in the registration and underwriting shall be allocated (i) first to the Company with respect to shares of Common Stock being sold for
its own account, (ii) second, to holders of Registrable Securities requesting registration in proportion, as 

  
 13 

 
nearly as practicable, to the respective amounts of securities owned by them and (iii) third, to Other Shareholders requesting registration in proportion, as nearly as practicable, to the
respective amounts of securities owned by them; provided that, with respect to any registration statement declared effective during the first six months following the IPO, at least twenty-five percent (25%) of the securities included in
such registration statement will be Registrable Securities. Notwithstanding the foregoing provisions, the Company may withdraw any registration statement referred to in this Section 4.4 without thereby incurring any liability to the holders of
Registrable Securities. If any holder of Registrable Securities disapproves of the terms of any such underwriting, it may elect to withdraw therefrom by written notice to the Company and the underwriter. Any Registrable Securities or other
securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. 
 4.5 Registration on Form S-3. In
addition to the rights provided in Sections 4.3 and 4.4, subject to a limit of one (1) registration hereunder in any six-month period, if at any time (i) any holder or holders of the Registrable Securities request that the Company file a
registration statement on Form S-3 or any comparable or successor form thereto for a public offering of all or any portion of the shares of Registrable Securities held by such requesting holder or holders, the reasonably anticipated aggregate price
to the public of which would be at least One Million Dollars ($1,000,000), and (ii) the Company is a registrant entitled to use Form S-3 or any comparable or successor form thereto to register such shares, then the Company shall use its
reasonable best efforts to register under the Securities Act on Form S-3 or any comparable or successor form thereto, for public sale in accordance with the method of disposition specified in such notice, the number of shares of Registrable
Securities specified in such notice. Whenever the Company is required by this Section 4.5 to use its reasonable best efforts to effect the registration of Registrable Securities, each of the procedures and requirements of Section 4.3,
including, but not limited to, the requirement that the Company notify all holders of Registrable Securities from whom notice has not been received and provide them with the opportunity to participate in the offering, shall apply to such
registration. If the holders requesting such registration notify the Company that they intend to distribute the Registrable Securities covered by their request by means of an underwriting, and if the managing underwriter in connection with such
underwriting determines that marketing factors require a limitation on the number of shares to be underwritten, then notwithstanding any other provision of this Section 4.5, such limitation will be imposed pro rata with respect to all
Registrable Securities whose holders have requested inclusion in such registration pursuant to this Section 4.5 provided that, in any event, all securities to be sold other than Registrable Securities will be excluded prior to any
exclusion of Registrable Securities. 
 4.6 Registration Procedures. If and whenever the Company is required by the provisions of
Section 4.3, 4.4 or 4.5 to use reasonable best efforts to effect the registration of any Registrable Securities under the Securities Act, the Company will, as expeditiously as possible: 

(a) prepare and file with the Commission a registration statement (which, in the case of an underwritten public offering pursuant to
Section 4.3, shall be on Form S-1 or other form of general applicability satisfactory to the managing underwriter selected as therein provided) with respect to such securities including executing an undertaking to file post-effective amendments
and use reasonable best efforts to cause such registration statement to become and remain effective for the period of the distribution contemplated thereby; 

  
 14 

 (b) prepare and file with the Commission such amendments and supplements to such
registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for the period specified herein and comply with the provisions of the Securities Act with respect to the
disposition of all Registrable Securities covered by such registration statement in accordance with the sellers’ intended method of disposition set forth in such registration statement for such period; 

(c) furnish to each seller of Registrable Securities and to each underwriter such number of copies of the registration statement and each
such amendment and supplement thereto (in each case including all exhibits) and the prospectus included therein (including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale or other
disposition of the Registrable Securities covered by such registration statement; 
 (d) use reasonable best efforts to register
or qualify the Registrable Securities covered by such registration statement under the securities or “blue sky” laws of such jurisdictions as the sellers of Registrable Securities or, in the case of an underwritten public offering, the
managing underwriter reasonably shall request, provided, however, that the Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so
qualified or to consent to general service of process in any such jurisdiction, unless the Company is already subject to service in such jurisdiction; 
 (e) use reasonable best efforts to list the Registrable Securities covered by such registration statement with any securities exchange on which the Common Stock of the Company is then listed; 

(f) comply with all applicable rules and regulations under the Securities Act and Exchange Act; 

(g) immediately notify each seller of Registrable Securities and each underwriter under such registration statement, at any time when a
prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event of which the Company has knowledge as a result of which the prospectus contained in such registration statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and promptly prepare and furnish
to such seller a reasonable number of copies of a prospectus supplemented or amended so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 
 (h) if the offering is underwritten and at the request of any seller of Registrable Securities, use reasonable best efforts to furnish on the date that Registrable Securities are delivered to the
underwriters for sale pursuant to such registration: (i) an opinion dated such date of counsel representing the Company for the purposes of such registration, addressed to the underwriters to such effects as reasonably may be requested by
counsel for the underwriters, and (ii) a letter dated such date from the independent public accountants retained by the Company, addressed to the underwriters stating that they are independent public accountants within the

  
 15 

 
meaning of the Securities Act and that, in the opinion of such accountants, the financial statements of the Company included in the registration statement or the prospectus, or any amendment or
supplement thereof, comply as to form in all material respects with the applicable accounting requirements of the Securities Act, and such letter shall additionally cover such other financial matters (including information as to the period ending no
more than five (5) business days prior to the date of such letter) with respect to such registration as such underwriters reasonably may request; 
 (i) make available for inspection by each seller of Registrable Securities, any underwriter participating in any distribution pursuant to such registration statement, and any attorney, accountant or other
agent retained by such seller or underwriter, reasonable access to all financial and other records, pertinent corporate documents and properties of the Company, as such parties may reasonably request, and cause the Company’s officers, directors
and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration statement; 
 (j) cooperate with the selling holders of Registrable Securities and the managing underwriter, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities
to be sold, such certificates to be in such denominations and registered in such names as such holders or the managing underwriter may request at least two (2) business days prior to any sale of Registrable Securities; and 

(k) permit any holder of Registrable Securities which holder, in the sole and exclusive judgment, exercised in good faith, of such
holder, might be deemed to be a controlling person of the Company, to participate in good faith in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to the Company in writing,
which in the reasonable judgment of such holder and its counsel should be included. 
 For purposes of this Agreement, the
period of distribution of Registrable Securities in a firm commitment underwritten public offering shall be deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of distribution of
Registrable Securities in any other registration shall be deemed to extend until the earlier of the sale of all Registrable Securities covered thereby or one hundred and eighty (180) days after the effective date thereof, provided,
however, in the case of any registration of Registrable Securities on Form S-3 or a comparable or successor form which are intended to be offered on a continuous or delayed basis, such 180-day period shall be extended, if necessary, to keep
the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and provided
further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment, permit, in lieu of filing a post-effective amendment which (y) includes any prospectus required by Section 10(a)(3)
of the Securities Act or (z) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in
(y) and (z) above contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement. 

  
 16 

 In connection with each registration hereunder, the sellers of Registrable Securities will
furnish to the Company in writing such information requested by the Company with respect to themselves and the proposed distribution by them as shall be reasonably necessary in order to assure compliance with Federal and applicable state securities
laws. 
 4.7 Expenses. 
 (a) All expenses incurred by the Company in complying with Sections 4.3, 4.4, 4.5 and 4.6 including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of
counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or “blue sky” laws, fees of the National Association of Securities Dealers,
Inc., transfer taxes, fees of transfer agents and registrars, costs of any insurance which might be obtained by the Company with respect to the offering by the Company, and reasonable fees and disbursements (not to exceed Thirty Thousand Dollars
($30,000)) of one counsel selected by a majority in interest of the sellers of Registrable Securities, but excluding any Selling Expenses (defined below), are called “Registration Expenses”. All underwriting discounts, underwriting
selling commissions and brokerage commissions applicable to the sale of Registrable Securities are called “Selling Expenses”. 
 (b) The Company will pay all Registration Expenses in connection with each registration statement under Section 4.3, 4.4 or 4.5. All Selling Expenses in connection with each registration statement
under Section 4.3, 4.4 or 4.5 shall be borne by the participating sellers in proportion to the number of shares registered by each, or by such participating sellers other than the Company (except to the extent the Company shall be a seller) as
they may agree. 
 4.8 Indemnification and Contribution. 
 (a) In the event of a registration of any of the Registrable Securities under the Securities Act pursuant to Section 4.3, 4.4 or 4.5, the Company will indemnify and hold harmless each holder of
Registrable Securities, its officers, directors, partners and employees, each underwriter of such Registrable Securities thereunder and each other person, if any, who controls such holder or underwriter within the meaning of the Securities Act,
against any losses, claims, damages or liabilities, joint or several, to which such holder, officer, director, partner, employee, underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in any prospectus, offering circular or other document incident to
such registration (including any related notification, registration statement under which such Registrable Securities were registered under the Securities Act pursuant to Section 4.3, 4.4 or 4.5, any preliminary prospectus or final prospectus
contained therein, or any amendment or supplement thereof), (ii) any blue sky application or other document executed by the Company specifically for that purpose or based upon written information furnished by the Company filed in any state or
other jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws thereof (any such application, document or information herein called a “Blue Sky Application”), (iii) any omission or
alleged omission to state in any such registration statement, prospectus, amendment or supplement or in any Blue Sky Applications executed or filed by the 

  
 17 

 
Company, a material fact required to be stated therein or necessary to make the statements therein not misleading, (iv) any violation by the Company or its agents of the Securities Act or
any rule or regulation promulgated under the Securities Act applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration, or (v) any failure to register or qualify the
Registrable Securities in any state where the Company or its agents has affirmatively undertaken or agreed in writing that the Company (the undertaking of any underwriter chosen by the Company being attributed to the Company) will undertake such
registration or qualification (provided that in such instance the Company shall not be so liable if it has used reasonable best efforts to so register or qualify the Registrable Securities) and will reimburse each such seller, and such
officer, director, partner and employee, each such underwriter and each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or
action, promptly after being so incurred, provided, however, that the Company will not be liable in any such case (i) if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue
statement or alleged untrue statement or omission or alleged omission so made in conformity with written information furnished by any such holder, any such underwriter or any such controlling person in writing specifically for use in such
registration statement or prospectus, or (ii) in the case of a sale directly by such holder of Registrable Securities (including a sale of such Registrable Securities through any underwriter retained by such holder of Registrable Securities to
engage in a distribution solely on behalf of such holder of Registrable Securities), such untrue statement or alleged untrue statement or omission or alleged omission was contained in a preliminary prospectus and corrected in a final or amended
prospectus, and such holder of Registrable Securities failed to deliver a copy of the final or amended prospectus at or prior to the confirmation of the sale of Registrable Securities to the person asserting any such loss, claim, damage or liability
in any case where such delivery is required by the Securities Act or any state securities laws. 
 (b) In the event of a
registration of any of the Registrable Securities under the Securities Act pursuant to Section 4.3, 4.4 or 4.5, each seller of such Registrable Securities thereunder, severally and not jointly, will indemnify and hold harmless the Company, each
person, if any, who controls the Company within the meaning of the Securities Act, each officer of the Company who signs the registration statement, each director of the Company, each other seller of Registrable Securities, each underwriter and each
person who controls any underwriter within the meaning of the Securities Act, against all losses, claims, damages or liabilities, joint or several, to which the Company or such officer, director, other seller, underwriter or controlling person may
become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact
contained in any prospectus offering circular or other document incident to such registration (including any related notification, registration statement under which such Registrable Securities were registered under the Securities Act pursuant to
Section 4.3, 4.4 or 4.5, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof), or any Blue Sky Application or arise out of or are based upon the omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and each such officer, director, other seller, underwriter and controlling person for any legal or other
expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, promptly after being 

  
 18 

 
so incurred, provided, however, that such seller will be liable hereunder in any such case if and only to the extent that any such loss, claim, damage or liability arises out of or
is based upon an untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading made in reliance upon
and in conformity with information pertaining to such seller, as such, furnished in writing to the Company by such seller specifically for use in such registration statement or prospectus; provided, however, that in no event shall any
indemnity hereinunder exceed the net proceeds from the offering received by such seller. Not in limitation of the foregoing, it is understood and agreed that the indemnification obligations of any seller hereunder pursuant to any underwriting
agreement entered into in connection herewith shall be limited to the obligations contained in this subparagraph (b). 
 (c)
Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party
in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have to such indemnified party other than under this Section 4.8 and shall only relieve it from any liability which it
may have to such indemnified party under this Section 4.8 if and to the extent the indemnifying party is substantially prejudiced by such omission. In case any such action shall be brought against any indemnified party and it shall notify the
indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel satisfactory to such indemnified party, and, after
notice from the indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 4.8 for any legal expenses
subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected, provided, however, that, if the defendants in any such action
include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the
indemnifying party or that the interests of the indemnified party reasonably may be deemed to conflict with the interests of the indemnifying party, the indemnified party shall have the right to select a separate counsel and to assume such legal
defenses and otherwise to participate in the defense of such action, with the expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the indemnifying party as incurred. No indemnifying party,
in the defense of any such claim or action, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or
plaintiff to such indemnified party of a release from all liability in respect to such claim or action. Each indemnified party shall furnish such information regarding itself or the claim in question as an indemnifying party may reasonably request
in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. 

(d) In order to provide for just and equitable contribution to joint liability under the Securities Act in any case in which either
(i) any holder of Registrable Securities exercising rights under this Agreement, or any controlling person of any such holder, makes a claim for indemnification pursuant to this Section 4.8 but it is judicially determined (by the entry of
a final 

  
 19 

 
judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case
notwithstanding the fact that this Section 4.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any such selling holder or any such controlling person in circumstances
for which indemnification is provided under this Section 4.8; then, and in each such case the Company and such holder will contribute to such aggregate losses, claims, damages or liabilities (i) in such proportion as is appropriate to
reflect the relative fault of the Company on the one hand and of such holder on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative fault referred to in clause (i) above but also reflective
of the relative benefits received by the Company on the one hand and by such holder on the other, provided, however, that, in any such case, no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The relative benefits received by the Company on the one hand and such holder on the other shall be deemed to be in the
same respective proportion as the total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by the Company and such holder. The relative fault of the Company on the one hand and of such
holder on the other shall be determined by reference to, among other things, whether the untrue statement or alleged untrue statement of a material fact or omission or alleged omission relates to information supplied by the Company or such holder
and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 (e) The indemnities and obligations provided in this Section 4.8 shall survive the transfer of any Registrable Securities by such holder. 
 4.9 Changes in Common Stock. If, and as often as, there is any change in the Common Stock by way of a stock split, stock dividend, combination or reclassification, or through a merger,
consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby shall continue with respect to the Common Stock as so changed.

 4.10 Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Commission which may at
any time permit the sale of the Registrable Securities to the public without registration, except as provided in paragraph (c) below, at all times after ninety (90) days after any registration statement covering a public offering of
securities of the Company under the Securities Act shall have become effective, the Company agrees to: 
 (a) make and keep
public information available, as those terms are understood and defined in Rule 144 under the Securities Act (or any successor rule); 
 (b) use reasonable best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and 

  
 20 

 (c) furnish to each holder of Registrable Securities forthwith upon request a written
statement by the Company as to its compliance with the reporting requirements of such Rule 144 (or any successor rule) and, at any time after it has become subject to such reporting requirements, of the Securities Act and the Exchange Act, a copy of
the most recent annual or quarterly report of the Company, and such other reports and documents so filed by the Company as such holder may reasonably request in availing itself of any rule or regulation of the Commission allowing such holder to sell
any Registrable Securities without registration. 
 4.11 “Market Stand-Off” Agreement. Each holder of Registrable Securities
agrees, if requested by the Company and an underwriter of Common Stock (or other securities) of the Company, (i) not to lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (whether such shares or
any such securities are then owned by such holder or are thereafter acquired), or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock,
whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, whether in privately negotiated or open market transactions, during the one
hundred and eighty (180) day period following the effective date of a registration statement of the Company filed under the Securities Act with respect to the Initial Public Offering, provided that all Other Shareholders, all officers
and directors of the Company, all Founders, all persons including shares in such offering and all holders of one percent (1%) or more of the outstanding shares of all classes of capital stock of the Company enter into similar agreements for
periods of equal or greater length. The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of said period. 

4.12 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Article 4 may be
assigned (but only with all related obligations) by a holder of Registrable Securities to a transferee or assignee of such securities (y) who is not an operating company engaged in a business activity directly competitive with the Company (as
reasonably determined by the Company’s Board of Directors) and who after such assignment or transfer, holds at least 50,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations and
similar recapitalization events); provided, however, no Investor shall be deemed to be engaged in a business activity directly competitive with the Company, or (z) who is an Affiliate or a constituent partner of such holder;
provided the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned;
and provided, further, that such assignment shall be effective only if (i) immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Securities Act and
(ii) the transferee or assignee shall acknowledge in writing that the transferred or assigned Registrable Securities shall remain subject to this Agreement. For the purposes of determining the number of shares of Registrable Securities held by
a transferee or assignee, the holdings of transferees and assignees of a partnership who are partners or retired partners of such partnership (including spouses and ancestors, lineal descendants and siblings of such partners or

  
 21 

 
spouses who acquire Registrable Securities by gift, will or intestate succession) shall be aggregated together and with the partnership; provided that all assignees and transferees who
would not qualify individually for assignment of registration rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any action under this Article 4. 

4.13 Conditions to Registration Obligations. The Company shall not be obligated to effect the registration of Registrable Securities pursuant to
Sections 4.3, 4.4 and 4.5 unless all holders of shares being registered consent to reasonable conditions imposed by the Company as the Company shall determine with the advice of counsel to be required by law including, without limitation:

 (a) conditions requiring such holder to comply with all prospectus delivery requirements of the Securities Act and with all
anti-stabilization, anti-manipulation and similar provisions of Section 10 of the Exchange Act and any rules issued thereunder by the Commission, and to furnish to the Company information about sales made in such public offering; and

 (b) conditions requiring the holders of Registrable Securities to enter into an underwriting agreement in form and substance
reasonably satisfactory to the Company and the holders of Registrable Securities. 
 4.14 Limitation on Subsequent Registration Rights.
The Company shall not grant to any Person any registration rights that in any way conflict with those contained herein, so long as any of the registration rights under this Agreement remains in effect, provided, in any event, (i) any
grant of demand, required or Form S-3 registration rights shall provide that the holders of Registrable Securities hereunder have incidental or “piggyback” registration rights with respect thereto in accordance with the provisions of
Section 4.4 hereof; (ii) such demand, required or Form S-3 registration rights shall not become effective prior to the rights of the holders of Registrable Securities hereunder, and (iii) any grant of incidental or
“piggyback” registration rights shall be junior in right of priority with the “piggyback” registration rights of holders of Registrable Securities hereunder. 
 4.15 No Conflict of Rights. The Company represents and warrants to each holder of Registrable Securities that other than the registration rights granted to the holders of the Company’s Series
A Convertible Preferred Stock., $.001 par value per share, the holders of the Company’s Series B Convertible Preferred Stock, $.001 par value per share, certain covenants by and between the Company and Tufts University
(“Tufts”) and Massachusetts Biotechnology Research Institute (“MBRI”), each pursuant to a certain Stock Subscription and Right of First Refusal Agreement dated March 31, 1997 by and between the Company and
Tufts and MBRI, respectively, and the registration rights granted hereby, there are no other registration rights granted by the Company. 
  

	5.	BOARD OF DIRECTORS 

 5.1 Election of
Directors. Each Stockholder shall take or cause to be taken such actions as may be required from time to time to establish and maintain the number of persons comprising 

  
 22 

 
the Board of Directors of the Company at nine (9) or at such other number (not to exceed ten (10)) as the Board of Directors (including at least one (1) Series H Director (as
defined below)) may determine from time to time, and to elect as directors (i) two (2) representatives of the Series C Stock, (A) one (1) of whom to be designated by Nomura International plc, and (B) one (1) of whom to
be elected by a majority of the holders of Series C Stock issued and outstanding (together with the representative designated under clause (A), the “Series C Directors”), (ii) two (2) representatives of the Series H Stock,
(A) one (1) of whom to be designated by Aisling Capital II, LP (initially Anthony Sun), and (B) one (1) of whom to be elected by a majority of the holders of Series H Stock issued and outstanding, (together with the
representative designated under clause (A), the “Series H Directors”), (iii) Walter Gilbert, Ph.D. or his designee, (iv) Stuart B. Levy, M.D. or his designee, (v) the Company’s Chief Executive Officer (who
currently is Thomas J. Bigger), and (vi) two (2) outside independent directors designated by Walter Gilbert, Ph.D., Stuart B. Levy, M.D. (or their respective designees) and the Company’s Chief Executive Officer (who currently are
Kenneth J. Novack and Pieter Strijkert, Ph.D., the “Outside Directors”); provided, however, in the event that the Series H Directors request in good faith that the size of the Board of Directors of the Company be
reduced to eight (8) for more efficient operation of such Board of Directors, such action will be taken as determined in good faith by, and with the approval of, the Company’s Chief Executive Officer, the Chairman of the Company’s
Board of Directors and the Series H Directors. Without limiting the generality of the foregoing, at each annual meeting of the stockholders, and at each special meeting of the stockholders called for the purpose of electing directors of the Company,
and at any time at which the stockholders have the right to, or shall, elect directors of the Company, then, and in each event, the Stockholders shall vote all Shares owned by them (or shall consent in writing in lieu of a meeting of stockholders,
as the case may be) to set the number of, and to elect persons as, directors of the Company in accordance with the preceding sentence. Notwithstanding anything contained herein or in that certain Securities Purchase Agreement, dated June 2,
2004, by and among the Series F Investors and the Company to the contrary, subject to applicable law, Nomura International plc’s director nominee shall be permitted to disclose to Nomura International plc all information and materials furnished
to directors at meetings or otherwise. 
 5.2 Removal of Directors; Filling of Vacancies. Notwithstanding anything to the contrary
contained herein, in the event that the size of the Board of Directors of the Company is reduced to eight (8) directors pursuant to Section 5.1 hereof, such reduction shall be effected by eliminating an Outside Director. Each Stockholder
shall take all action necessary to remove forthwith any director when such removal is requested for any reason, with or without cause, by the Persons that designated such director for election. In the case of the death, resignation or removal as
herein provided of a director, each Stockholder shall vote all Shares owned by him, her or it to elect another person designated by the Persons that designated the deceased, resigning or removed director if, at the time such vacancy occurs, such
Persons shall have the right to have a person designated by them elected as a director pursuant to Section 5.1. If any Person that is entitled to designate or elect, as the case may be, a director pursuant to Section 5.1 fails to designate
or elect a sufficient number of directors to fill all directorships for which they are entitled to designate or elect pursuant to Section 5.1, then any directorship not so filled shall remain vacant until such time as such Person designates or
elects an individual to fill such directorship; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to designate or elect a person to fill such directorship.
At any meeting held for the purpose of electing a director, the presence in 

  
 23 

 
person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such
director. Except as otherwise provided in this Section 5.2, a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series
or by any remaining director or directors elected by the holders of such class or series pursuant to this Section 5.2. 
 5.3 Company
Committees; Directors of Subsidiaries. The Company’s Board of Directors shall establish a Compensation Committee (the “Compensation Committee”) consisting of the Chairman of the Board, one Board member elected by the
holders of the Series C Stock and one other Board member that is not an executive officer or otherwise affiliated with an executive officer of the Company. The Compensation Committee will be authorized by the Board of Directors (i) to establish
compensation for senior management of the Company, (ii) to grant shares of Common Stock, Rights or Convertible Securities and other forms of compensation under the Company’s option plans or other equity arrangements and (iii) to make
recommendations to the Board of Directors regarding the recruitment and termination of senior management. Notwithstanding anything contained herein to the contrary, each Series H Director shall be entitled to become a member of any committee of the
Board of Directors of the Company, including, but not limited to, the Compensation Committee, as well as a member of the Board of Directors of any Subsidiary of the Company. 
 5.4 Board Observer Rights. The holders of a majority of outstanding shares of Series D Stock and, as long as Aisling Capital II, LP owns not less than ten percent (10%) of the Series H Stock
it purchased pursuant to the Securities Purchase Agreement, Aisling Capital II, LP shall each have the right to designate one representative, reasonably acceptable to the Company, who shall be entitled to attend all meetings of the Company’s
Board of Directors in a non-voting observer capacity, and to receive copies of all materials that the Company provides to its directors, provided that such representatives shall maintain the confidentiality of all information provided
to them in such materials and in the course of their attendance at meetings of the Company’s Board of Directors, and provided further that such representatives may be excluded from any “executive session” of the Board of
Directors at which, in the opinion of the Chairman of the Board of Directors exercised in good faith, such exclusion is necessary to preserve or protect the exercise of the Board of Directors’ fiduciary duties, to preserve the attorney-client
privilege, to protect confidential information or to avoid a conflict of interest. The representative of Aisling Capital II, LP entitled to the rights set forth in this Section 5.4 shall initially be Dov Goldstein. 

5.5 Contingent Expansion of the Board. If, at any time after the fourth anniversary of the Series H Original Issue Date, a Triggering Event (as
hereinafter defined) occurs, the number of persons then comprising the Board of Directors of the Company shall be increased automatically from nine (9) to fifteen (15) and the Board of Directors shall be reconstituted (the
“Reconstituted Board of Directors”) such that there shall be (i) two (2) Series C Directors, two (2) Series H Directors and two (2) Outside Directors, in each case as required by Section 5.1 hereof,
(ii) three (3) directors, other than the Outside Directors, elected by the holders of Common Stock and of any other class or series of voting stock (including the Series C Stock and Series H Stock), voting together as a separate class, who
shall be Walter Gilbert, Ph.D. or his designee, Stuart B. Levy, M.D. or his designee, and the Company’s Chief Executive Officer, and 

  
 24 

 
(iii) six (6) directors elected by the Selling Investors identified in Section 3.5 hereof, voting together as a single class; provided, however, if the number of persons
comprising the Board of Directors of the Company at the time of the Triggering Event is eight (8), as permitted by Section 5.1 hereof, then the number of Outside Directors shall be one (1) and the total number of directors elected pursuant
to clause (iii) above shall be five (5); provided, further, if the number of persons comprising the Board of Directors of the Company at the time of the Triggering Event is ten (10), as permitted by Section 5.1 hereof, then
the total number of directors elected pursuant to clause (iii) above shall be seven (7). For the purposes hereof, a “Triggering Event” shall occur when both of the following events take place: (a) the Selling Investors
identified in Section 3.5 hereof approve the merger or consolidation of the Company with or into another Person in which the Company’s stockholders will receive cash or securities of any other Person for their shares, thereby causing the
Stockholders to be obligated to participate in such transaction pursuant to Section 3.5 hereof (a “Merger”), and (b) the Board of Directors of the Company, after receipt of a bona fide offer regarding the Merger (in
the form of a term sheet or otherwise), elects not to approve the Merger at a duly called meeting or via written consent. Notwithstanding anything contained herein to the contrary, the Board of Directors of the Company shall only be expanded to
become the Reconstituted Board of Directors pursuant to this Section 5.5 solely for the purpose of obtaining approval by the Reconstituted Board of Directors of the Merger and the actions directly related thereto that are the subject of a
Triggering Event. In the event that the consummation of such Merger fails to occur for any reason within the time period set forth in any bona fide term sheet or other writing related to the Merger, in each case as may be amended or extended from
time to time, or in the event that any action unrelated to such Merger is required to be voted on, the composition of the Board of Directors of the Company shall automatically revert back to the composition in effect immediately prior to the
Reconstituted Board of Directors becoming effective. The rights and obligations contained in this Section 5.5 relating to the Merger that is the subject of a Triggering Event may be waived only by the Selling Investors identified in
Section 3.5 hereof, voting together as a single class. 
 5.6 Reimbursement of Expenses. The Company shall promptly reimburse
members of its Board of Directors and any observer permitted by Section 5.4 for reasonable travel and other out-of-pocket expenses incurred by them in connection with their attendance at meetings of the Company’s Board of Directors or
committees thereof. If requested by the Company, such directors and observers shall provide the Company with documentation supporting any such expenses. 
 5.7 Termination of Article. The provisions of this Article 5 shall be of no further force or effect upon the consummation of the Company’s Initial Public Offering. 

 

	6.	NEGATIVE COVENANTS OF THE COMPANY. 

6.1 The Company covenants and agrees that it will not, without first having obtained the affirmative vote or written consent of the holders of at
least sixty-six and two-thirds percent (66-2/3%) of the outstanding shares of Series C Stock, take any of the actions set forth in the following covenants and provisions: 
 (a) Amendments to the Charter and By-Laws. The Company will not amend the Certificate of Incorporation or By-Laws of the Company in any way which adversely affects the rights of the holders of the
Series C Stock. 

  
 25 

 (b) Reclassification of Capital Stock. The Company will not reclassify any other
class of capital stock into shares having any preference or priority as to assets superior to that of the Series C Stock. 
 (c)
Authorization of Capital Stock. The Company will not authorize or issue any shares of capital stock having any preferences or priority as to dividends or assets upon liquidation superior to that of the Series C Stock. 

6.2 The Company covenants and agrees that it will not, without first having obtained the affirmative vote or written consent of the holders of at
least sixty-six and two-thirds percent (66-2/3%) of the outstanding shares of the Series C Stock, the Series D Stock, the Series F Stock and the Series H Stock, voting together as a single class, take any of the actions set forth in the following
covenants and provisions: 
 (a) Distributions. Neither the Company nor any
Subsidiary will purchase, redeem, retire, or otherwise acquire for value any shares of its capital stock (or rights, options or warrants to purchase such shares) now or hereafter outstanding, or return any capital to its stockholders, and neither
the Company nor any Subsidiary shall declare or pay any dividends or make any distribution of assets to its stockholders as such, except for repurchases of shares of Common Stock held by employees, consultants, directors, or officers of the Company
that are subject to stock repurchase agreements under which the Company has the right to repurchase such shares in the event of termination of employment.  
 (b) Merger and Sale of Assets; Liquidation and Dissolution. The Company will not merge or consolidate with any other Person or sell, assign, lease or otherwise dispose of all or substantially all
of its assets, in one transaction or in a series of transactions, nor dissolve, reorganize or liquidate the Company. 
 (c)
Indebtedness. The Company will not incur indebtedness in excess of Five Million Dollars ($5,000,000) outstanding at any time unless such indebtedness has been approved by each of the Series C Directors and the Series H Directors. 

(d) Option Plans and Equity Arrangements. The Company will not establish any new option plans or equity compensation arrangements.

 (e) Dealings with Affiliates. The Company will not enter into any transaction or agreement, other than indemnification
pursuant to statutory law and other than employment transactions in the ordinary course of the Company’s business approved in accordance with Section 5.3, with any employee, officer or director or any member of their families, or any
corporation or other entity in which any one or more of such persons holds, directly or indirectly, five percent (5%) or more of any class of capital stock, or with any other Affiliate of the Company, unless such transaction or agreement has
been approved by the each of the Series C Directors and the Series H Directors. 

  
 26 

 (f) Acquisitions. The Company will not purchase or acquire any stock or other
securities of, or all or substantially all of the assets or properties of, any Person, if such Person (or such assets) would constitute ten percent (10%) or more of the net worth of the Company. 

6.3 Termination of Negative Covenants. The covenants set forth in this Article 6 shall be of no further force or effect upon the consummation of
the Company’s Initial Public Offering. 
  

	7.	AFFIRMATIVE COVENANTS OF THE COMPANY 

 The Company covenants and agrees that, from the date of the Closing under the Securities Purchase Agreement and thereafter so long as any Investor owns Registrable Securities, it will perform and observe
the following covenants and provisions, and will cause each Subsidiary, if and when such Subsidiary exists, to perform and observe the following covenants and provisions as applicable to such Subsidiary. 

7.1 Financial Statements; Other Reports. The Company will maintain proper books of account and records in accordance with generally accepted
accounting principles applied on a consistent basis, and will deliver to each Investor and its Affiliates jointly owning at least two hundred and fifty thousand (250,000) shares of the Company’s capital stock, treating all Preferred Stock
on an as converted basis but excluding any unexercised options, warrants or purchase rights (each, a “Rights Holder”): 
 (a) as soon as available and in any event within forty five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, a balance sheet of the Company as
of the end of such quarter and the related statements of income and stockholders’ equity and of cash flows of the Company for the period commencing at the end of the previous fiscal year and ending with the end of such quarter, setting forth in
each case in comparative form the corresponding figures for the corresponding period of the preceding fiscal year and the budget for such current year, all in reasonable detail and prepared in accordance with generally accepted accounting principles
consistently applied; 
 (b) as soon as available and in any event within ninety (90) days after the end of each fiscal
year of the Company, a copy of the annual audit report for such year for the Company, including therein a balance sheet of the Company as of the end of such fiscal year and statements of income and stockholders’ equity and of cash flows of the
Company for such fiscal year, setting forth in each case in comparative form the corresponding figures for the preceding fiscal year, all duly certified by independent public accountants of recognized standing acceptable to the Rights Holders;

 (c) as soon as available and in any event within forty five (45) days after the end of each of the first 11 months of
each fiscal year of the Company, a balance sheet of the Company as of the end of such month and the related statements of income and stockholders’ equity for the period commencing at the end of the previous fiscal year and ending with the end
of such month, setting forth in each case in comparative form the corresponding figures for the corresponding period of the preceding fiscal year and the budget for such current year, all in reasonable detail and prepared in accordance with
generally accepted accounting principles consistently applied; 

  
 27 

 (d) as soon as available and, in any event at least thirty (30) days prior the start of
each fiscal year, a copy of the business plan for such year, including operating budgets, operating expenses and profit and loss projections, cash flow projections and capital expenditure budgets, as prepared for the Board of Directors and as
approved by the Board of Directors; and 
 (e) promptly after sending, making available, or filing the same, such reports and
financial statements as the Company shall send or make available to the stockholders of the Company. 
 7.2 Inspection and Other
Information. Each Rights Holder and such agents, advisors and counsel as such Rights Holder may designate, may, at its expense, visit and inspect any of the properties of the Company, examine the books of account of the Company, take extracts
therefrom and discuss the affairs, finances and accounts of the Company with its officers and employees at reasonable times and with reasonable prior notice during normal business hours. All such visits and inspections shall be conducted in a manner
which will not unreasonably interfere with the normal business operations of the Company. The Company will furnish to each such Rights Holder such other information as it from time to time may reasonably request. In addition, the Company will
provide such Rights Holders with a written notice reasonably describing the initiation of any legal action against the Company that, in the good faith determination of the Board of Directors, could have a material adverse effect on the Company.

 7.3 Maintenance of Key-Person Life and Director and Officer Liability Insurance. The Company will maintain, with a financially sound
and reputable insurance company or association, (i) term life insurance on the life of Stuart B. Levy, M.D., in the amount of Three Million Dollars ($3,000,000), which proceeds shall be payable to the order of the Company and (ii) director
and officer liability insurance pursuant to terms and in amounts that, in the good faith determination of the Company’s Board of Directors, is reasonable. The Company will not cause or permit any assignment of the proceeds of such policies or
change in beneficiaries, and will not borrow against such policies. The Company will include the Investors as a notice party to such policies, and will request that the issuer of each such policy provide each Investor with twenty
(20) days’ notice before the respective policy is terminated (for failure to pay premiums or otherwise) or assigned, or before any change is made in the designation of the beneficiary thereof. 

7.4 Preservation of Corporate Existence. The Company will preserve and maintain its corporate existence, rights, franchises and privileges in the
jurisdiction of its incorporation, and qualify and remain qualified, as a foreign corporation in each jurisdiction in which such qualification is necessary or desirable in view of its business and operations or the ownership of its properties.

 7.5 Availability of Common Stock. The Company will, from time to time, in accordance with the laws of the State of Delaware, increase
the authorized amount of Common Stock if at any time the number of shares of Common Stock remaining unissued and available for issuance shall be insufficient to permit conversion of all then outstanding shares of Investor Preferred Stock.

  
 28 

 7.6 Termination of Affirmative Covenants. The covenants set forth in this Article 7 shall be of no
further force or effect upon the consummation of the Company’s Initial Public Offering. 
  

	8.	MISCELLANEOUS 

 8.1 Notices. All
notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party’s address set forth below or to such other address as a party may designate by notice hereunder, and shall be either
(i) delivered by hand, (ii) made by telecopy or facsimile transmission, (iii) sent by overnight courier, or (iv) sent by registered or certified mail, return receipt requested, postage prepaid. 

 

					
	If to an Investor:	    	To its address set forth on its signature page hereto or on the Exhibit pages attached hereto:
		
	If to the Company:	    	Paratek Pharmaceuticals, Inc.
		    	75 Kneeland Street
		    	Boston, MA 02111
		    	Tel:	  	(617) 275-0040
		    	Fax:	  	(617) 275-0039
		    	Attn:	  	Beverly A. Armstrong
		
	With a copy to:	    	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
		    	One Financial Center
		    	Boston, MA 02111
		    	Tel:	  	(617) 542-6000
		    	Fax:	  	(617) 542-2241
		    	Attn:	  	Lewis J. Geffen, Esq.

 All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i) if
by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by telecopy or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic
confirmation or otherwise, (iii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the fifth business day following
the day such mailing is made, provided that, registered or certified mail shall not be used to effectuate delivery of any such notices, requests, consents and other communications to Investors located in any foreign country.

 8.2 Entire Agreement. This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the
subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement
shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 
 8.3 Modifications and
Amendments. This Agreement may not be amended or modified, and no provision hereof may be waived, without the written consent of the Company and the holders of at least sixty-six and two-thirds percent (66-2/3%) of the outstanding shares of

  
 29 

 
Investor Preferred Stock; provided that without the consent of a majority of the holders of Series H Stock, no amendment, modification or waiver shall be made (i) to
Section 3.5 or (ii) to Section 5.1, 5.3 or 5.4 (which, in the case of Section 5.1, 5.3 or 5.4, would affect the holders of Series H Stock); provided that if an amendment, modification or waiver would adversely
affect any holder of Investor Preferred Stock in a manner that does not similarly adversely affect all holders of Investor Preferred Stock, the consent of such holder shall be required, and provided further, that without the consent of
each Founder, no amendment, modification or waiver shall be made which affects such Founders. Any waiver or consent hereunder shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a
continuing waiver or consent. 
 8.4 Assignment. The rights and obligations under this Agreement may not be assigned by the Company
without the prior written consent of the holders of at least a majority of the Registrable Securities, unless specifically permitted by the terms hereof. 
 8.5 Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective
successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this
Agreement. 
 8.6 Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance
with and governed by the law of the State of Delaware, without giving effect to the conflict of law principles thereof. 
 8.7 Venue. Any
legal action or proceeding with respect to this Agreement shall be brought in the courts of the Commonwealth of Massachusetts or of the United States of America for the District of Massachusetts. 

8.8 Severability. In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in
this Agreement shall be unenforceable in any respect, then such provision shall be deemed limited to the extent that such court deems it enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem
any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect. 
 8.9 Interpretation. The parties hereto acknowledge and agree that: (i) each party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its
revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be
construed fairly as to all parties hereto and not in favor of or against any party, regardless of which party was generally responsible for the preparation of this Agreement. 
 8.10 Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify or affect the meaning or
construction of any of the terms or provisions hereof. 

  
 30 

 8.11 Enforcement. Each of the parties hereto acknowledges and agrees that the rights acquired by each
party hereunder are unique and that irreparable damage would occur in the event that any of the provisions of this Agreement to be performed by the other parties were not performed in accordance with their specific terms or were otherwise breached.
Accordingly, in addition to any other remedy to which the parties hereto are entitled at law or in equity, each party hereto shall be entitled to an injunction or injunctions to prevent breaches of this Agreement by any other party and to enforce
specifically the terms and provisions hereof in any federal or state court to which the parties have agreed hereunder to submit to jurisdiction. 
 8.12 No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing among the parties
hereto, shall operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such
right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of
such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other
circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand. 
 8.13 Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 [Signature pages follow] 

  
 31 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth above.

  

			
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Beverly A. Armstrong

		 	Beverly A. Armstrong
		 	Vice President, Chief Compliance Officer & General Counsel

  
 32 

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and. Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

			
	AISLING CAPITAL II, LP
		
	By:	 	 /s/ Andrew P. Nicholson

	Name:	 	 Andrew P. Nicholson

	Title:	 	 Treasurer

	
	Address:
	
	 Aisling Capital II, LP
 c/o Aisling Capital

		
	Date:	 	  

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company” and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

					
	D. E. Shaw Composite Portfolios, L.L.C.
	By:	 	D. E. Shaw & Co., L.L.C., as managing member
			
		 	 By:
	 	 /s/ James Mackey

		 		 	Name: James Mackey
		 		 	Title: Authorized Signatory

  

			
	Address:	 	
		 	
		 	

 
			
		
	Date:	 	 October 5, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19 , 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Hercules Technology Growth Capital, Inc.

	Printed Name of Stockholder
	
	 /s/ Scott Harvey

	Signature of Stockholder
	Chief Legal Officer
	Hercules Technology Growth Capital, Inc.

  

			
	Title:	 	 Chief Legal Officer

			
		
	Address:	 	  

		
		 	  

 
			
		
	Date:	 	 10/10/2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Boston Life Sciences Venture Corp.

	Printed Name of Stockholder
	
	 /s/ Peter T.K. Wu

	Signature of Stockholder

  

			
	Title:	 	 Chairman

			
		
	Address:	 	  

		
		 	  

 
			
		
	Date:	 	  

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this Counterpart
Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 PGE Venture Fund, LLC

	Printed Name of Stockholder
	
	 /s/ Thomas Dietz

	Signature of Stockholder

  

			
	Name:	 	 Thomas Dietz

			
		
	Title:	 	 Managing Member, PGE Venture Fund
LLC

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October 15, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007(the “Agreement”), among Paratek Pharmaceuticals, Inc, (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Sarah L Gordon

	Printed Name of Stockholder
	
	 /s/ Sarah L Gordon

	Signature of Stockholder

  

			
	Title:	 	 Mrs. Sarah Gordon

			
		
	Address:	 	  

		
		 	 
		
		 	  

 
			
		
	Date:	 	 12th Oct 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 William Slattery

	Printed Name of Stockholder
	
	 /s/ William Slattery

	Signature of Stockholder

  

			
	Name:	 	 William S Slattery

			
		
	Title:	 	  

 

			
		
	Address:	 	  

		
		 	  

 
			
		
	Date:	 	 10/19/07

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Novartis Bioventures Ltd

	Printed Name of Stockholder
	
	 /s/ Emil Bock

	Signature of Stockholder

  

			
	Name:	 	 Emil Bock

			
		
	Title:	 	 Deputy Chairman

			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October 15, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Nomura Phase 4 Ventures LP

	Printed Name of Stockholder
	
	 /s/ D. Pollard-Knight

	Signature of Stockholder

  

			
	Name:	 	 Dr. D. Pollard-Knight, Nomura

	 Phase 4 Ventures Limited acting as manager

	 for Nomura Phase 4 Ventures
LP

 
			
		
	Title:	 	 Head of Phase 4 Ventures

			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 16 October 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Bio Fund Ventures II Follow-On L.P.

	Printed Name of Stockholder
	
	 /s/ Kalevi Kurkijarvi

	Signature of Stockholder

  

			
	Name:	 	 Kalevi Kurkijarvi

			
		
	Title:	 	 General Partner

			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 16th Oct., 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 HBM Bio Fund Ventures (Cayman) Ltd.

	Printed Name of Stockholder
	
	 /s/ John Arnold

	Signature of Stockholder

  

			
	Name:	 	 John Arnold

			
		
	Title:	 	 Chairman and Managing
Director

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October     , 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of October
19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this Counterpart
Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Lombard Order Darier Hentsch

	Printed Name of Stockholder
	
	 /s/ by proxy

	Signature of Stockholder

  

			
	Name:	 	 /s/ Alexandra Meyer    /s/ Eric
Menotti

 
			
		
	Title:	 	 Executive Vice President    Vice
President

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 Oct.18, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 BioVeda Fund Pte Ltd

	Printed Name of Stockholder
	
	 /s/ Damien Lim

	Signature of Stockholder

  

			
	Name:	 	 BioVeda Capital Pte Ltd, its Investment
Manager

 
			
		
	Title:	 	 Damien Lim, General
Partner

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 17 October 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Kenneth J. Novack, et al

	Printed Name of Stockholder
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Name:	 	 Patrick B. Maraghy

			
		
	Title:	 	 Agent

 
			
		
	Address:	 	 RINET Company LLC

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October 16, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 PRAG Associates LLC

	Printed Name of Stockholder
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Name:	 	 Patrick B. Maraghy

			
		
	Title:	 	 Agent

 
			
		
	Address:	 	 RINET Company LLC

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October 16, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Peter S. Lawrence

	Printed Name of Stockholder
	
	 /s/ Peter S. Lawrence

	Signature of Stockholder

  

			
	Name:	 	 Peter S. Lawrence

			
		
	Title:	 	  

 

			
		
	Address:	 	  

		
		 	  

		
		 	  

 

			
		
	Date:	 	  

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Patricia A. Suzman

	Printed Name of Stockholder
	
	 /s/ Patricia A. Suzman

	Signature of Stockholder

  

			
	Title:	 	  

 

			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 10/18/2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 John P Dunphy

	Printed Name of Stockholder
	
	 /s/ John P Dunphy

	Signature of Stockholder

  

			
	Name:	 	 John P Dunphy

			
		
	Title:	 	  

 

			
		
	Address:	 	  

		
		 	  

		
		 	  

 

			
		
	Date:	 	  

							
	 /s/ Stuart B. Levy, M.D.
	 		 	Date:	 	Oct 9, 2007
				
	Stuart B. Levy, M.D.	 		 		 	
				
	 /s/ C. Pastel Levy
	 		 	Date:	 	10/9, 2007
	Cecile P. Levy	 		 		 	

  

									
	The Stuart and Cecile Levy Irrevocable Trust – 1996
					
	By:	 	 /s/ David Pastel
	 		 	Date:	 	10/09/, 2007

									
					
	Name:	 	 David Pastel
	 		 		 	

									
					
	Title:	 	 Trustee
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	 /s/ Walter Gilbert, Ph.D
	 		 	Date:	 	  
	 	
	Walter Gilbert, Ph.D	 		 		 		 	
					
	 /s/ Cecile Gilbert
	 		 	Date:	 	  
	 	
	Cecile Gilbert	 		 		 		 	
					
	 /s/ John Gilbert
	 		 	Date:	 	 10/9/07
	 	
	John R. Gilbert	 		 		 		 	
					
	 /s/ Kate Gilbert
	 		 	Date:	 	 10/9/07
	 	
	Kate Gilbert	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	Tufts University	 	
					
	By:	 	 /s/ Margaret E. Newell
	 		 	Date:	 	10/9/07

									
					
	Name:	 	 Margaret E. Newell
	 		 		 	

									
					
	Title:	 	 Vice Provost
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	Craig L. Burr 1985 Childrens Trust	 		 	
					
	By:	 	 /s/ Francis F. Kingsley
	 		 	Date:	 	October 9, 2007

									
					
	Name:	 	 Francis F. Kingsley
	 		 		 	

									
					
	Title:	 	 Administrator UPOA
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

					
	 /s/ Frederick Frank
	 		 	Date:                  , 2007
			
	Frederick Frank	 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	Genechem Therapeutics Venture Fund L.P.	 		 	
					
	By:	 	 /s/ Martial Lacroix
	 		 	Date:	 	September     , 2007

									
					
	Name:	 	 Martial Lacroix
	 		 		 	

									
					
	Title:	 	 VP GeneChem Management, Inc
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	 /s/ Irwin M. Heller
	 		 	Date:	 	 Oct 6, 2007
	 	
	Irwin M. Heller	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	 /s/ Peter S. Lawrence
	 		 	Date:	 	 10.10.07
	 	
	Peter S. Lawrence	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

											
	Lombard Odier Darier Hentsch	 		 		 	
				
	 Successor to/On behalf of 
 Lombard Darier Hentsch & Cie
 Lombard Odier & Cie
	 		 		 	
					
	By:	 	 /s/ Alexandra
Meyer                /s/ Eric Menotti
	 		 	Date:	 	Oct 10th, 2007

											
					
	Name:	 	 Alexandra
Meyer                Eric Menotti
	 		 		 	

											
					
	Title:	 	 Executive Vice
President            Vice President
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	Mintz Levin Investments L.L.C	 		 	
					
	By:	 	 /s/ Jeffrey M. Wiesen
	 		 	Date:	 	10/5, 2007

									
					
	Name:	 	 Jeffrey M. Wiesen
	 		 		 	

									
					
	Title:	 	 Manager
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

											
	Novartis Bio Ventures Ltd	 		 		 		 	
						
	By:	 	 /s/ Emil Bock
	 		 	Date:	 	 9/10/2007
	 	

											
						
	Name:	 	 Emil Bock
	 		 		 		 	

											
						
	Title:	 	 Deputy Chairman of the Board of Directors
	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	 /s/ R. Robert Popeo
	 		 	Date:	 	 10/5/07
	 	
	R. Robert Popeo	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

											
	Schweizerhall Holding AG	 		 		 		 	
						
	By:	 	 /s/ L.v. Bidder
	 		 	Date:	 	 9.10.2007
	 	

											
						
	Name:	 	 L. von Bidder
	 		 		 		 	

											
						
	Title:	 	 VRP
	 		 		 		 	
						
		 	/s/ M. Von Ah	 		 		 		 	
						
		 	M. Von Ah	 		 		 		 	
						
		 	CFO	 		 		 		 	

											
	 /s/ Harold Snyder
	 		 	Date:	 	Oct 8, 2007	 	
	Harold Snyder	 		 		 		 	
					
	HBJ Investments, LLC	 		 		 		 	
						
	By:	 	 /s/ Harold Snyder
	 		 	Date:	 	Oct 8, 2007	 	

											
	Name:	 	 Harold Snyder
	 		 		 		 	

											
	Title:	 	 Partner
	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	FSC Corp.	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Becky Levin	 		 		 		 		 	
						
	Bio Fund Ventures II Ky/L.P.	 		 		 		 		 	

													
							
	By:	 	 /s/ Kalevi Kurkijarvi
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 Kalevi Kurkijarvi
	 		 		 		 		 	

													
	Title:	 	 General Partner
	 		 		 		 		 	

													
						
	Bio Fund Ventures II Jaticofijoitusrahasto Ky	 		 		 		 		 	

													
							
	By:	 	 /s/ Kalevi Kurkijarvi
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 Kalevi Kurkijarvi
	 		 		 		 		 	

													
	Title:	 	 General Partner
	 		 		 		 		 	

													
						
	BankInvest Biomedical Development I	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	BankInvest Biomedical Development II	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Mintz Levin Investment LLC	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Merifin Capital N.V.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Craig L. Burr 1986 Childrens Trust	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Charles and Ruth Levy	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Frederick Frank	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Frederick Frank – Lehman Brothers,	 		 		 		 		 	

													
	Custodian for Frederick Frank IRA	 		 		 		 		 	

													
	Account No. 	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	R. Robert Popeo	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Irwin M. Heller	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Peter S. Lawrence	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	David Novack	 		 		 		 		 	

													
	
	Nomura Phase4 Ventures Limited as manager for Nomura International plc

													
							
	By:	 	 /s/ Denise Pollard - Knight
	 		 	Date:	 	 16/10/07
	 	,	 	

													
	Name:	 	 Dr. Denise Pollard - Knight
	 		 		 		 		 	

													
	Title:	 	 Head of Phase4 Ventures
	 		 		 		 		 	

													
						
	Lombard Odier & Cie	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

											
	  
	 		 	Date:	 	  
	 	,	 	
	Anthony John Khuri	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Miriam and Steven White	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Hyman Novack	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Helen Novack	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Judy and Peter Smith	 		 		 		 		 	
						
	Novack Associates Limited Partnership II	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B. Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B. Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	

													
						
	Novartis BioVentures Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	HBM VioVentures (Cayman) Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	POD Holding, Inc.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	  
	 		 	Date:	 	  
	 	,	 	
	Anthony John Khuri	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Miriam and Steven White	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Hyman Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Helen Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Judy and Peter Smith	 		 		 		 		 	
						
	Novack Associates Limited Partnership II	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Novartis BioVentures Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	HBM BioVentures (Cayman) Ltd.	 		 		 		 		 	

													
							
	By:	 	 /s/ John Arnold
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 John Arnold
	 		 		 		 		 	

													
	Title:	 	 Chairman and Managing Director
	 		 		 		 		 	

													
						
	POD Holding, Inc.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	  
	 		 	Date:	 	  
	 	,	 	
	Anthony John Khuri	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Miriam and Steven White	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Hyman Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Helen Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Judy and Peter Smith	 		 		 		 		 	
						
	Novack Associates Limited Partnership II	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Novartis BioVentures Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	HBM VioVentures (Cayman) Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	POD Holding, Ltd	 		 		 		 		 	

													
							
	By:	 	 /s/ Peter Lawrence
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 Peter S. Lawrence
	 		 		 		 		 	

													
	Title:	 	 Director
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Erhvervsudviklingsforeningen BankInvest Biomedicinsk Venture I	 		 	
							
	By:	 	 /s/ Jens Kindtler
	 		 	Date:	 	 Oct 10, 2007
	 	,	 	

													
	Name:	 	 Jens Kindtler
	 		 		 		 		 	

													
	Title:	 	 Partner
	 		 		 		 		 	
						
	A/S BI Biomedicinsk Venture II	 		 		 		 		 	

													
							
	By:	 	 /s/ Jens Kindtler
	 		 	Date:	 	 Oct 10, 2007
	 	,	 	

													
	Name:	 	 Jens Kindtler
	 		 		 		 		 	

													
	Title:	 	 Partner
	 		 		 		 		 	
						
	P/S BI Biomedicinsk Venture III	 		 		 		 		 	

													
							
	By:	 	 /s/ Jens Kindtler
	 		 	Date:	 	 Oct 10, 2007
	 	,	 	

													
	Name:	 	 Jens Kindtler
	 		 		 		 		 	

													
	Title:	 	 Partner
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Lahive & Cockfield, LLP	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Lehman Brothers As Custodian	 		 		 		 		 	
	For David Pastel IRA	 		 		 		 		 	
	Account No. 	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Formosa Healthcare Investments, L.P.	 		 		 		 		 	
							
	By:	 	 /s/ Howard Lee
	 		 	Date:	 	 Sept. 27, 2007
	 	,	 	

													
	Name:	 	 Howard Lee
	 		 		 		 		 	

													
	Title:	 	 General Partner
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Alden I. Gifford	 		 		 		 		 	
						
	Rockwood Capital Corporation	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	William G. Coughlin	 		 		 		 		 	
						
	Wheatley Med Tech Partners, LP	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Bioveda Fund Pte Ltd.	 		 		 		 		 	
							
	By:	 	 /s/ Damien Lim
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Anthony John Khuri	 		 		 		 		 	
						
	Lehman Brothers	 		 		 		 		 	
	As Custodian For Jay Levy	 		 		 		 		 	
	IRA Account # 	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Lehman Brothers	 		 		 		 		 	
	As Custodian For Sharon Levy	 		 		 		 		 	
	IRA Account	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Genechem Therapeutics Venture Fund L.P.	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	BI Biomedical Venture III	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	  
	 		 	Date:	 	  
	 	,	 	
	Harold Snyder	 		 		 		 		 	
						
	HBJ Investments	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Jay Linn Trustee, Irrevocable Trust	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Norman and Suzanne Priebatsch	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Robert D. Ritchie	 		 		 		 		 	
						
	Winchester Capital Healthcare Partners	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Kenneth J. Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Ellen and Mario Koenig	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	David F. Pastel	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Jay and Sharon Levy	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Donald M. Phillips	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Winchester Capital Technology Partners	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	David R. Novack	 		 		 		 		 	
						
	K.B. (C.I.) Nominees Limited	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	BioFund Ventures II, L.P	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Squamata Limited	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Schweizerhall Investment Ltd.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Novack Associates Ltd Ptrshp II	 		 		 		 		 	
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	
						
	Novack Associates L.P.	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	
						
	Jeffrey N. Novack 1996 Trust	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	
						
	Madeline Gunilla Pontin 1997 Trust	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	

													
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Kenneth J. Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	David Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Emily K. Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Sara E. Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Helen Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Hyman Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Laura Novack Pontin	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Judy and Peter Smith	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Miriam and Steven White	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Craig L. Burr 1986 Childrens Trust	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Charles and Ruth Levy	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Frederick Frank	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Frederick Frank – Lehman Brothers,	 		 		 		 		 	
	Custodian for Frederick Frank IRA	 		 		 		 		 	
	Account No. 	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	R. Robert Popeo	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Irwin M. Heller	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Peter S. Lawrence	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	David Novack	 		 		 		 		 	
						
	Nomura International plc	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Lombard Odier & Cie	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Lahive & Cockfield, LLP	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Lehman Brothers As Custodian	 		 		 		 		 	
	For David Pastel IRA	 		 		 		 		 	
	Account No. 	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	China Development Industrial Bank Inc.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Alden I. Gifford	 		 		 		 		 	
						
	Rockwood Capital Corporation	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	William G. Coughlin	 		 		 		 		 	
						
	Wheatley Med Tech Partners, LP	 		 		 		 		 	

													
							
	By:	 	 /s/ Barry Rubenstein
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 Barry Rubenstein
	 		 		 		 		 	

													
	Title:	 	 CEO Wheatley Med Tech
	 		 		 		 		 	
		 	 Partners, LLC, General Partner
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

  

													
	  
	 		 	Date:	 	  
	 		 	
	Walter Gilbert, Ph.D	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	Cecile Gilbert	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	Stuart B. Levy, M.D.	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	Cecile P. Levy	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	John R. Gilbert	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	Kate Gilbert	 		 		 		 		 	
						
	Tufts University	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 		 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	The Stuart and Cecile Levy Irrevocable Trust – 1996	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 		 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	PRAG Associates, LLC	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 		 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

 EXHIBIT A 

FOUNDERS 
 The
Stuart and Cecile Levy 1996 Trust 
 Stuart B. Levy, M.D. 
 Cecile P. Levy, M.D. 
 Walter Gilbert, Ph.D. 

Celia Gilbert 
 John R. Gilbert 

Kate Gilbert 
 Tufts University 

Licensing Office 

  
 A-1

 EXHIBIT B 

SERIES C INVESTORS 

Nomura International plc 
 Lombard
Odier & Cie 
 FSC Corp. 

Kenneth J. Novack 
 Becky Levin 

Bio Fund Ventures II Ky 
 BANKINVEST

 Biomedical Development I & II 

Merifin Capital N.V. 
 c/o Finabel S.A., 254
route de Lausanne, 
 Harold Snyder 

c/o HBJ Investments, LLC 

  
 B-1

 HBJ Investments, LLC 
 Mintz Levin Investment LLC 
 c/o Mintz, Levin, Cohn, Ferris, 

Glovsky and Popeo, P.C. 
 Jay
Linn Trustee, Irrevocable Trust 
 Agreement Number III 
 Norman and Suzanne Priebatsch 
 Robert D. Ritchie 

Lehman Brothers as Custodian for David Pastel 

IRA Account No.  
 c/o Amy Mavrogian

 Lehman Brothers 
 Winchester Capital
Healthcare Partners LLC 
 c/o Pensar N. Anquillare, President 
 Lehman Brothers, Custodian for Frederick 
 Frank IRA Account No.  

Jay and Sharon Levy 

  
 B-2

 Ellen and Mario Koenig 
 Miriam and Steven White 
 c/o RINET Company, LLC 

Hyman Novack 
 c/o RINET Company, LLC

 Helen Novack 
 c/o RINET Company,
LLC 
 David Novack 
 c/o RINET
Company, LLC 
 Judy and Peter Smith 

c/o RINET Company, LLC 
 Novack Associates
Limited Partnership II 
 c/o RINET Company, LLC 
 Anthony John Khuri 

  
 B-3

 Donald J. M. Phillips 
 c/o Ted Thomas Associates 

  
 B-4

 EXHIBIT C 

SERIES D INVESTORS 

Novartis BioVentures Ltd. 
 Hurst Holme

 HBM BioVentures (Cayman) Ltd. 
 HBM
BioVentures AG 
 POD Holding, Inc. 

Kenneth J. Novack 
 Lahive &
Cockfield, LLP 
 Formosa Healthcare Investments, L.P. 
 c/o Howard Lee, Ph.D. 
 Wheatley MedTech Partners, LP 

			
	 With copies to:
	 	Wheatley Partners

  
 C-1

 FSC Corp. 
 c/o BancBoston Capital Inc. 
 Alden I. Gifford 

Rockwood Capital Corporation 
 c/o David H.
Carls 
 William G. Coughlin 
 Lehman
Brothers as Custodian for 
 David Pastel IRA Account No.  
 Lehman Brothers 
 BioVeda Fund Pte Ltd 
 Ellen and Mario Koenig 
 Lehman Brothers as Custodian for 

Sharon Levy IRA Account No.  

  
 C-2

 Lehman Brothers as Custodian for 
 Jay Levy IRA Account No.  
 Anthony Khuri 

c/o Khuri Consulting Group 
 Robert Ritchie

 Peter S. Lawrence 
 GeneChem
Therapeutics 
 Venture Fund L.P 

BankInvest 
 BI Biomedical Venture III

 Nomura International PLC 
 Mintz
Levin Investments, LLC 
 Mintz, Levin, Cohn, 
 Ferris, Glovsky and Popeo, P.C. 
 Irwin Heller 

  
 C-3

 Harold Snyder 
 HBJ Investments, LLC 
 PRAG Associates LLC 

c/o RINET Company, LLC 
 Merifin Capital N.V.

 c/o Finabel SA 
 Lombard
Odier & Cie 
 c/o Lombard Odier Darier Hentsch Group 
 Winchester Capital Technology 
 Partners LLC 

K.B.(C.I.) Nominees Limited 
 Bio Fund Ventures
II L.P. 
 Squamata Limited 

  
 C-4

 EXHIBIT D 

SERIES F INVESTORS 

June 2, 2004 
 POD Holding,
Inc. 
 Novartis BioVentures Ltd. 

Frederick Frank 
 Anthony John Khuri

 c/o Khuri Consulting Group 
 R.
Robert Popeo 
 Peter S. Lawrence 

Lahive & Cockfield, LLP 
 Kenneth J.
Novack 
 Novack Associates Limited Partnership II 
 c/o RINET Company, LLC 

  
 D-1

 David Novack 
 c/o RINET Company, LLC 
 Jeffrey N. Novack 1996 Irrevocable Trust dated 2/14/96, Marianne M.
Novack, David R. Novack and Paul D. Bishop, Trustee 
 c/o RINET Company, LLC 
 Judy and Peter Smith 
 c/o RINET Company, LLC 

Hyman Novack 
 c/o RINET Company, LLC

 Helen Novack 
 c/o RINET Company,
LLC 
 Miriam and Steven White 
 c/o
RINET Company, LLC 
 Bio Fund Ventures II L.P. 
 Robert Cawthorn 

  
 D-2

 Emily K. Novack 
 c/o RINET Company, LLC 
 Sara E. Novack 
 c/o RINET Company, LLC 
 Madeline Gunilla Pontin 1997 Trust 

c/o RINET Company, LLC 
 Laura Novack Pontin

 c/o RINET Company, LLC 

June 11, 2004 
 Lombard
Darier Hentsch & Cie 
 Schweizerhall Holding AG 
 BioVeda Fund Pte Ltd 

  
 D-3

 Wheatley Med Tech Partners, LP 

 

			
	 With copies to:
	 	Wheatley Partners

 Rosemary Nguyen 

  
 D-4

 EXHIBIT E 

SERIES H INVESTORS 

Aisling Capital II, LP 
 c/o Aisling Capital

 With a copy to: 
 McKee Nelson LLP 
 D.E. Shaw Composite Portfolios, L.L.C. 

Hercules Technology Growth Capital, Inc. 

Boston Life Science Venture Corp. 
 PGE Venture
Fund, LLC 
 Sarah L. Gordon 

  
 E-1

 William Slattery 
 Novartis BioVentures Ltd 
 Nomura Phase4 Ventures LP 

Bio Fund Ventures II Follow-On L.P. 
 HBM
BioVentures (Cayman) Ltd. 
 Lombard Odier Darier Hentsch 
 BioVeda Fund Pte Ltd 
 Kenneth J. Novack 
 c/o RINET Company, LLC 

  
 E-2

 PRAG Associates LLC 
 c/o RINET Company, LLC 
 Jeffrey N. Novack 1996 Trust 

c/o RINET Company, LLC 
 Emily K. Novack

 c/o RINET Company, LLC 
 Sara E.
Novack 
 c/o RINET Company, LLC 

Madeline Gunilla Pontin 1997 Present Interest Trust 
 c/o RINET Company, LLC 
 David Novack 
 c/o RINET Company, LLC 
 Judy & Peter Smith 

c/o RINET Company, LLC 
 Novack Family 1999
Trust f/b/o Emily Kate Novack 
 c/o RINET Company, LLC 

  
 E-3

 Novack Family 1999 Trust f/b/o Jeffrey Novack 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o Sarah Elizabeth Novack 

c/o RINET Company, LLC 
 Novack Family 1999
Trust f/b/o Laura Pontin 
 c/o RINET Company, LLC 
 Helen Novack 
 c/o RINET Company LLC 
 Hyman Novack 
 c/o RINET Company, LLC 
 Miriam and Steven White 
 c/o RINET Company, LLC 

Laura Novack Pontin 
 c/o RINET Company, LLC

  
 E-4

 David and Lesley Novack 
 c/o RINET Company, LLC 
 Marianne M. Novack 

c/o RINET Company, LLC 
 Peter S. Lawrence

 Patricia A. Suzman 
 John P. Dunphy

  
 E-5

 PARATEK PHARMACEUTICALS, INC. 

FIRST AMENDMENT 
 TO THE 
 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 This First Amendment (the “Amendment”) to the Third Amended and Restated Investor Rights Agreement,
dated October 19, 2007, by and among (i) Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), (ii) the holders of the Company’s common stock listed on Exhibit A (referred to herein
individually as a “Founder” and collectively as the “Founders”), (iii) the Series C Investors listed on Exhibit B (the “Series C Investors”), (iv) the Series D Investors listed on
Exhibit C (the “Series D Investors”), (v) the Series F Investors listed on Exhibit D (the “Series F Investors”) and (vi) the Series H Investors listed on Exhibit E (the “Series
H Investors” and together with the Series C Investors, Series D Investors, Series F Investors, the “Investors”), is made as of August 6, 2009. 
 WHEREAS, the Company is entering into a Note Purchase Agreement with certain existing stockholders of the Company pursuant to which the Company will issue and sell and these certain stockholders will
purchase promissory notes of the Company; 
 WHEREAS, in connection with the execution of the Note Purchase Agreement, the
Company, the Investors and the Founders desire to amend certain provisions of Section 5 of the Investor Rights Agreement as set forth herein in order to modify the size and composition of the Company’s Board of Directors; and 

WHEREAS, in accordance with Section 8.3 of the Investor Rights Agreement, (i) Investors holding at least sixty-six and
two-thirds percent (66-2/3%) of the outstanding shares of the Investor Preferred Stock (as defined in the Investor Rights Agreement), (ii) Investors holding a majority of the outstanding shares of Series H Stock (as defined in the Investor
Rights Agreement) and (iii) the Founders have, in each case, provided their written consent and approval of this Amendment, and, by executing and delivering this Amendment, the Company has consented and approved of this Amendment. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained in this Amendment and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1.
Amendment of Investor Rights Agreement. 
 (i) The Investor Rights Agreement is hereby amended by deleting
Section 5.1 in its entirety and by substituting in lieu thereof the following new Section 5.1: 
 “5.1 Election
of Directors. Each Stockholder shall take or cause to be taken such actions as may be required from time to time to establish and maintain the number of persons comprising the Board of Directors of the Company at ten (10) or at such other
number as the Board of Directors (including at least one (1) Series H Director (as defined below)) may determine from time to time, and to elect as directors (i) two (2) representatives of the Series C Stock, (A) one (1) of
whom to be designated by Nomura 

 
International plc, and (B) one (1) of whom to be elected by a majority of the holders of Series C Stock issued and outstanding (together with the representative designated under clause
(A), the “Series C Directors”), (ii) three (3) representatives of the Series H Stock, to be designated by Aisling Capital II, LP (the “Series H Directors”), one of whom shall initially be Anthony Sun, MD
(iii) Walter Gilbert, Ph.D. or his designee, (iv) Stuart B. Levy, M.D. or his designee, (v) the Company’s Chief Executive Officer (who currently is Thomas J. Bigger), and (vi) two (2) outside independent directors
designated by Walter Gilbert, Ph.D., Stuart B. Levy, M.D. (or their respective designees) and the Company’s Chief Executive Officer (who currently are Kenneth J. Novack and Pieter Strijkert, Ph.D., the “Outside Directors”);
provided, however, in the event that less than all three Series H Directors are present at any meeting of the Board of Directors, then (1) in the event one Series H Director is present, such Series H Director shall have the right
to cast three votes and (2) in the event two Series H Directors are present, one of whom is Anthony Sun, then Dr. Sun shall have the right to cast two votes, in each case so that the Series H Director(s) shall have the right to cast three
(3) votes. Without limiting the generality of the foregoing, at each annual meeting of the stockholders, and at each special meeting of the stockholders called for the purpose of electing directors of the Company, and at any time at which the
stockholders have the right to, or shall, elect directors of the Company, then, and in each event, the Stockholders shall vote all Shares owned by them (or shall consent in writing in lieu of a meeting of stockholders, as the case may be) to set the
number of, and to elect persons as, directors of the Company in accordance with the preceding sentence. Notwithstanding anything contained herein or in that certain Securities Purchase Agreement, dated June 2, 2004, by and among the Series F
Investors and the Company to the contrary, subject to applicable law, Nomura International plc’s director nominee shall be permitted to disclose to Nomura International plc all information and materials furnished to directors at meetings or
otherwise.” 
 (ii) Section 5.2 of the Investor Rights Agreement is hereby amended by deleting the first sentence of
Section 5.2 in its entirety. 
 (iii) The Investor Rights Agreement is hereby amended by deleting Section 5.5 in its
entirety and by substituting in lieu thereof the following new Section 5.5: 
 “5.5 Contingent Expansion of the
Board. If, at any time after the fourth anniversary of the Series H Original Issue Date, a Triggering Event (as hereinafter defined) occurs, the number of persons then comprising the Board of Directors of the Company shall be increased
automatically from ten (10) to fifteen (15) and the Board of Directors shall be reconstituted (the “Reconstituted Board of Directors”) such that there shall be (i) two (2) Series C Directors, three
(3) Series H Directors and two (2) Outside Directors, in each case as required by Section 5.1 hereof, (ii) three (3) directors, other than the Outside Directors, elected by the holders of Common Stock and of any other class
or series of voting stock (including the Series C Stock and Series H Stock), voting together as a separate class, who shall be Walter Gilbert, Ph.D. or his designee, Stuart B. Levy, M.D. or his designee, and the Company’s Chief Executive
Officer, and (iii) five (5) directors elected by the Selling Investors identified in Section 3.5 hereof, voting together as a single class; provided, however, if the number of persons comprising the Board of Directors of
the Company at the time of the Triggering Event is less than or more than ten (10), then 

  
 2 

 
the total number of directors elected pursuant to clause (iii) above shall be such number of directors as, together with the three (3) Series H Directors, is sufficient to constitute a
majority of the full Board of Directors. For the purposes hereof, a “Triggering Event” shall occur when both of the following events take place: (a) the Selling Investors identified in Section 3.5 hereof approve the merger
or consolidation of the Company with or into another Person in which the Company’s stockholders will receive cash or securities of any other Person for their shares, thereby causing the Stockholders to be obligated to participate in such
transaction pursuant to Section 3.5 hereof (a “Merger”), and (b) the Board of Directors of the Company, after receipt of a bona fide offer regarding the Merger (in the form of a term sheet or otherwise), elects not
to approve the Merger at a duly called meeting or via written consent. Notwithstanding anything contained herein to the contrary, the Board of Directors of the Company shall only be expanded to become the Reconstituted Board of Directors pursuant to
this Section 5.5 solely for the purpose of obtaining approval by the Reconstituted Board of Directors of the Merger and the actions directly related thereto that are the subject of a Triggering Event. In the event that the consummation of such
Merger fails to occur for any reason within the time period set forth in any bona fide term sheet or other writing related to the Merger, in each case as may be amended or extended from time to time, or in the event that any action unrelated to such
Merger is required to be voted on, the composition of the Board of Directors of the Company shall automatically revert back to the composition in effect immediately prior to the Reconstituted Board of Directors becoming effective. The rights and
obligations contained in this Section 5.5 relating to the Merger that is the subject of a Triggering Event may be waived only by the Selling Investors identified in Section 3.5 hereof, voting together as a single class.” 

2. Miscellaneous. 
 Except as contemplated by this Amendment, all of the terms and conditions of the Investor Rights Agreement shall remain in full force and effect. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 3 

 IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first above
written. 
  

			
	
	COMPANY:
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Thomas J. Bigger

	Name: Thomas J. Bigger
	Title:   President and Chief Executive Officer

 Signature Page to First Amendment to Third Amended and Restated Investor Rights Agreement

 EXHIBIT A 

FOUNDERS 
 The
Stuart and Cecile Levy 1996 Trust 
 Stuart B. Levy, M.D. 
 Cecile P. Levy, M.D. 
 Walter Gilbert, Ph.D. 

Celia Gilbert 
 John R. Gilbert 

Kate Gilbert 
 Tufts University 

Licensing Office 

  
 Exhibit A-1

 EXHIBIT B 

SERIES C INVESTORS 

Nomura International plc 
 Omega Fund III, L.P.

 c/o Omega Fund Management Limited 

FSC Corp. 
 Kenneth J. Novack 

Becky Levin 
 Bio Fund Ventures II Ky

 BANKINVEST 
 Biomedical Development
I & II 
 Merifin Capital N.V. 

c/o Finabel S.A. 
 Harold Snyder 

c/o HBJ Investments, LLC 

  
 Exhibit B-1

 HBJ Investments, LLC 
 Mintz Levin Investment LLC 
 c/o Mintz, Levin, Cohn, Ferris, 

Glovsky and Popeo, P.C. 

Irrevocable Trust Agreement Number I, Jay Howard Linn, Trustee 
 Norman and Suzanne Priebatsch 
 Robert D. Ritchie 

Barclays Capital Inc. as Custodian for David Pastel IRA No.  
 Winchester Capital Healthcare Partners LLC 
 c/o Pensar N. Anquillare, President 

Barclays Capital Inc. as Custodian for Frederick Frank IRA No.  
 Jay and Sharon Levy 
 Ellen and Mario Koenig 

  
 Exhibit B-2

 Miriam and Steven White 
 c/o RINET Company, LLC 
 Hyman Novack 
 c/o RINET Company, LLC 
 Helen Novack 
 c/o RINET Company, LLC 
 David Novack 
 c/o RINET Company, LLC 
 Judy and Peter Smith 

c/o RINET Company, LLC 
 Novack Associates
Limited Partnership II 
 c/o RINET Company, LLC 
 Marianne M. Novack 
 c/o RINET Company, LLC 

  
 Exhibit B-3

 Kenneth J. Novack 1993 Revocable Trust 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o 

Emily K. Novack 
 c/o RINET Company, LLC

 Novack Family 1999 Trust f/b/o Jeffrey Novack 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o Sara Elizabeth Novack 

c/o RINET Company, LLC 
 Novack Family 1999
Trust f/b/o Laura Pontin 
 c/o RINET Company, LLC 
 Marianne M. Novack 
 c/o RINET Company, LLC 

Anthony John Khuri 
 c/o Khuri Consulting Group

 Donald J. M. Phillips 
 c/o Ted
Thomas Associates 

  
 Exhibit B-4

 EXHIBIT C 

SERIES D INVESTORS 

Novartis BioVentures Ltd. 
 HBM BioVentures
(Cayman) Ltd. 
 HBM BioVentures AG 

POD 1.0 AB (Reg No. 556744-9466) 
 Kenneth
J. Novack 
 L&C Participation, LLC 
 Ralph A. Loren, Personal 
 DeAnn F. Smith, Personal 

Formosa Healthcare Investments, L.P. 
 c/o
Howard Lee, Ph.D. 

  
 Exhibit C-1

 Wheatley MedTech Partners, LP 

			
	 With copies to:
	 	Wheatley Partners

 FSC Corp. 
 c/o
BancBoston Capital Inc. 
 Alden I. Gifford 
 Rockwood Capital Corporation 
 c/o David H. Carls 

William G. Coughlin 
 Barclays Capital Inc. as
Custodian for David Pastel IRA 
 BioVeda Fund Pte Ltd 
 Ellen and Mario Koenig 
 Barclays Capital Inc. as Custodian for Sharon Levy IRA No. 

  
 Exhibit C-2

 Barclays Capital Inc. as Custodian for Jay Levy IRA No. 

Anthony Khuri 
 c/o Khuri Consulting Group

 Robert Ritchie 
 Peter S. Lawrence

 GeneChem Therapeutics 
 Venture Fund
L.P 
 BankInvest 
 BI Biomedical
Venture III 
 Nomura International PLC 
 Mintz Levin Investments, LLC 
 Mintz, Levin, Cohn, 

Ferris, Glovsky and Popeo, P.C. 

Irwin Heller 

  
 Exhibit C-3

 Harold Snyder 
 HBJ Investments, LLC 
 PRAG Associates LLC 

c/o RINET Company, LLC 
 Merifin Capital N.V.

 c/o Finabel SA 
 Omega Fund III,
L.P. 
 c/o Omega Fund Management Limited 
 Winchester Capital Technology 
 Partners LLC 

David R. Novack 
 c/o RINET Company, LLC

 Peter and Judy Smith 
 c/o RINET
Company, LLC 
 Steven and Miriam White 

c/o RINET Company, LLC 

  
 Exhibit C-4

 K/S Danish Bioventure 
 Collier International Partners IV Limited 
 c/o Collier Capital 

POD Venture Partners AB (Reg. No. 556744-9441) 
 Robert E. Cawthorne 
 Bio Fund Ventures II L.P. 

Squamata Limited 

  
 Exhibit C-5

 EXHIBIT D 

SERIES F INVESTORS 

POD 1.0 AB (Reg No. 556744-9466) 

Novartis BioVentures Ltd. 
 Frederick Frank

 Anthony John Khuri 
 c/o Khuri
Consulting Group 
 R. Robert Popeo 

Robert Cawthorn 
 Peter S. Lawrence 

L&C Participation, LLC 
 DeAnn F. Smith,
PERSONAL 

  
 Exhibit D-1

 Kenneth J. Novack 
 David Novack 
 c/o RINET Company, LLC 
 Jeffrey N. Novack 1996 Irrevocable Trust dated 2/14/96, Marianne M. Novack, David R. Novack and Paul D. Bishop, Trustee 
 c/o RINET Company, LLC 
 Judy and Peter Smith 

c/o RINET Company, LLC 
 Hyman Novack

 c/o RINET Company, LLC 
 Helen
Novack 
 c/o RINET Company, LLC 

Miriam and Steven White 
 c/o RINET Company, LLC

 Bio Fund Ventures II L.P. 

  
 Exhibit D-2

 Emily K. Novack 
 c/o RINET Company, LLC 
 Sara E. Novack 
 c/o RINET Company, LLC 
 Madeline Gunilla Pontin 1997 Trust 

c/o RINET Company, LLC 
 Laura Novack Pontin

 c/o RINET Company, LLC 
 Omega Fund
III, L.P. 
 c/o Omega Fund Management Limited 
 BioVeda Fund Pte Ltd 
 BioFund Ventures II Follow-On Fund L.P. 

  
 Exhibit D-3

 Wheatley Med Tech Partners, LP 

			
	 With copies to:
	 	Wheatley Partners

 Rosemary Nguyen 

  
 Exhibit D-4

 EXHIBIT E 

SERIES H INVESTORS 

Aisling Capital II, LP 
 c/o Aisling Capital

 With a copy to: 
 McDermott Will & Emery 
 D.E. Shaw Valence Portfolios, L.L.C. 

Hercules Technology Growth Capital, Inc. 

Boston Life Science Venture Corp. 
 Thomas J.
Dietz 
 c/o Wedbush Morgan Securities 

The Osgood Family Trust UAD 4/14/2000 
 c/o
Wedbush Morgan Securities 

  
 Exhibit E-1

 The Osgood Family Trust UAD 4/14/2000 
 c/o Wedbush Morgan Securities 
 Ben Perkins Custodian for William Beau Perkins Uniform Gift to
Minors Act CA 
 c/o Wedbush Morgan Securities 
 Ben Perkins Custodian for Charlotte Rose Perkins Uniform Gift to Minors Act CA 
 c/o Wedbush Morgan
Securities 
 The Ingram Family Trust U/A/D 11/23/96, as amended, Gregory J. Ingram & Heidi M. Ingram, Trustees 

c/o Wedbush Morgan Securities 
 Sarah L. Gordon

 Novartis BioVentures Ltd 
 Nomura
Phase4 Ventures LP 
 Bio Fund Ventures II Follow-On L.P. 

  
 Exhibit E-2

 HBM BioVentures (Cayman) Ltd. 
 Omega Fund III, L.P. 
 c/o Omega Fund Management Limited 

BioVeda Fund Pte Ltd 
 Kenneth J. Novack

 c/o RINET Company, LLC 
 PRAG
Associates LLC 
 c/o RINET Company, LLC 
 Jeffrey N. Novack 1996 Trust 
 c/o RINET Company, LLC 

Emily K. Novack 
 c/o RINET Company, LLC

 Sara E. Novack 
 c/o RINET Company,
LLC 

  
 Exhibit E-3

 Madeline Gunilla Pontin 1997 Present Interest Trust 
 c/o RINET Company, LLC 
 David Novack 
 c/o RINET Company, LLC 
 Judy & Peter Smith 

c/o RINET Company, LLC 
 Novack Family 1999
Trust f/b/o Emily Kate Novack 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o Jeffrey Novack 
 c/o RINET Company, LLC 

Novack Family 1999 Trust f/b/o Sarah Elizabeth Novack 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o Laura Pontin 

c/o RINET Company, LLC 
 Helen Novack

 c/o RINET Company LLC 

  
 Exhibit E-4

 Hyman Novack 
 c/o RINET Company, LLC 
 Miriam and Steven White 

c/o RINET Company, LLC 
 Laura Novack Pontin

 c/o RINET Company, LLC 
 David and
Lesley Novack 
 c/o RINET Company, LLC 

Marianne M. Novack 
 c/o RINET Company, LLC

 Peter S. Lawrence 
 Patricia A.
Suzman 
 John P. Dunphy 

  
 Exhibit E-5

 PARATEK PHARMACEUTICALS, INC. 

ACKNOWLEDGEMENT, CONSENT AND SECOND AMENDMENT 
 TO THE 
 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 This Acknowledgement, Consent and Second Amendment (the “Amendment”) to the Third Amended and Restated
Investor Rights Agreement, dated October 19, 2007, as amended (the “Investor Rights Agreement”), by and among (i) Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), (ii) the
Founders party thereto, (iii) the Series C Investors listed on Exhibit B (the “Series C Investors”), (iv) the Series D Investors listed on Exhibit C (the “Series D Investors”), (v) the
Series F Investors listed on Exhibit D (the “Series F Investors”) and (v) the Series H Investors listed on Exhibit E (the “Series H Investors” and together with the Series C Investors, and Series
D Investors, Series F Investors, the “Investors”), is made as of November 29, 2010 and is effective as of the completion of the Transaction (as defined below). 

WHEREAS, the Company has been notified by Nomura International Plc (“NIP”), a holder of the Company’s Series C
Convertible Preferred Stock and Series D Convertible Preferred Stock and by Nomura Phase4 Ventures LP (“NPV2”), a holder of the Company’s Series H Convertible Preferred Stock (collectively the “NPV Stock”) that
NIP and NPV2 are in the process of transferring the entirety of the NPV Stock (together with all of the rights attached thereto) to a limited partnership to be known as Phase4 Ventures III LP (the “Transferee”); 

WHEREAS, the initial investor in the Transferee will be a Nomura entity (being an affiliate of NIP and of the sole Nomura investor in
NPV2), but it is intended that such affiliate will dispose of its limited partnership interest to a fund managed or advised by HarbourVest Partners, LLC or its affiliates, which will become the new majority limited partner in the Transferee;

 WHEREAS, Nomura Phase4 Ventures Limited (“NPVL”), the current manager of the NPV Stock for NIP and NPV2 will
also be appointed to manage the Transferee, and an affiliate of NPVL will be the general partner of each of the Transferee and NPV2; 
 WHEREAS, concurrently with the disposal of the limited partnership interest in the Transferee, NIP will transfer NPVL and its subsidiaries to the current management team comprising NPVL (the
“Transaction”); 
 WHEREAS, based on the foregoing, the Transaction will constitute a transfer by NIP and NPV2
to an “Affiliate” of such Stockholders and will thus constitute a transfer to a “Permitted Transferee” for purposes of Section 3.6 of the Investor Rights Agreement, such that the provisions of Sections 3.3, 3.4 and 3.5 of
the Investor Rights Agreement will not apply to the Transaction; 

 WHEREAS, each of NIP and NPV2 intend to assign all of their respective rights under the
Investor Rights Agreement to the Transferee and the Transferee will assume all of the obligations of NIP and NPV2 under the Investor Rights Agreement by executing an Instrument of Adherence to the Investor Rights Agreement in substantially the form
attached hereto as Exhibit A; 
 WHEREAS, while it is anticipated that NPV2 and the Transferee will remain under the
common management of NPVL, (i) the limited partnership agreement governing NPV2 contains provisions relating to the removal of the general partner and termination of the manager, and negotiated terms in relation to these provisions will be
included in the limited partnership governing the Transferee and (ii) NPV2 and the Transferee do not have the same term, as NPV2’s term is due to expire on 30 April 2012 (although it may be extended by two additional one year
periods); while this is not envisaged, it is therefore possible that NPV2 and the Transferee may cease to be commonly managed at some point in the future or that NPV2 may be dissolved prior to the liquidation of the Transferee; and 

WHEREAS, in accordance with Section 8.3 of the Investor Rights Agreement, Investors holding at least sixty-six and two-thirds
percent (66-2/3%) of the outstanding shares of the Investor Preferred Stock (as defined in the Investor Rights Agreement), have provided their written consent to, and approval of, this Amendment, and, by executing and delivering this Amendment, the
Company has consented to and approved this Amendment. 
 NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained in this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 

1. Acknowledgement of Permitted Transferee. 
 The parties hereby confirm and acknowledge that the transfer of the NPV Stock by each of NIP and NPV2 to the Transferee is a transfer to an “Affiliate” (under and as defined in the Investor
Rights Agreement) and that the Transferee is a “Permitted Transferee” under Section 3.6 of the Investor Rights Agreement. 
 2. Amendment to Investor Rights Agreement. 
 Section 5.1 of the
Investor Rights Agreement is hereby amended such that each reference to “Nomura International Plc” is replaced with a reference to “Phase4 Ventures III LP”, such that the rights exercisable by NIP to designate one Series C
Director to the Board of Directors of the Company be exercisable by the Transferee going forwards. For purposes of clarification, the parties acknowledge that any other rights to elect persons to the Board of Directors of the Company which NIP (as
Series C and Series D Stockholder) and NPV2 (as Series H Stockholder) may have had pursuant to Article 5 of the Investor Rights Agreement shall be exercisable by the Transferee following completion of the Transaction. 

3. Effect of Amendment. 
 Except as contemplated by this Amendment, the terms and conditions of the Investor Rights Agreement shall remain in full force and effect. 

  
 2 

 4. Counterparts. This Amendment may be executed in one or more counterparts, and by
different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 5. Governing Law. This Amendment will be governed by and interpreted and construed in accordance with the internal laws of the State of Delaware, without giving effect to the conflict of law
principles thereof. 
 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above written.

  

			
	COMPANY:
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Beverly Armstrong

	Name:	 	Beverly Armstrong
	Title:	 	Vice President, Chief Compliance Officer, General Counsel and Secretary

 [counterpart signature pages for Investors follow] 

  
 3 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Aisling Capital II, LP

	Printed Name of Stockholder
	
	 /s/ Lloyd Appel

	Signature of Stockholder

  

			
	Title:	 	 Lloyd Appel, CFO

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 11/1/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 BioVeda Fund Pte Ltd

	Printed Name of Stockholder
	
	 /s/ BioVeda Fund Pte Ltd

	Signature of Stockholder

  

			
	Title:	 	 By BioVeda Capital Pte Ltd,

		 	 its Investment Manager

		 	 Damien Lim, General Partner

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 10/25/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 William G. Coughlin

	Printed Name of Stockholder
	
	 /s/ William G. Coughlin

	Signature of Stockholder

  

			
	Title:	 	  

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 D.E. Shaw Valence Portfolios, L.L.C.

	Printed Name of Stockholder
	
	 /s/ Anne Dinning

	Signature of Stockholder

  

			
	Title:	 	 Managing Director

 

			
	 Address:
	 	  

		
		 	  

		
		 	  

 

			
	 Date:
	 	 10/27/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Thomas J. Dietz

	Printed Name of Stockholder
	
	 /s/ Thomas J. Dietz

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/20/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Frederick Frank

	Printed Name of Stockholder
	
	 /s/ Frederick Frank

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Alden I. Gifford

	Printed Name of Stockholder
	
	 /s/ Alden I. Gifford

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 25 Oct 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Beryl L. Snyder, Partner

	Printed Name of Stockholder
	
	 /s/ Beryl L. Snyder, Partner

	Signature of Stockholder

  

			
	Title:	 	 Partner

 

			
	Address:	 	 HBJ Investments, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 26, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 HBM BioVentures (Cayman) Ltd.

	Printed Name of Stockholder
	
	 /s/ John Arnold

	Signature of Stockholder

  

			
		 	John Arnold
	Title:	 	 Chairman & Managing
Director

  

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 22 Oct/2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Irwin Heller

	Printed Name of Stockholder
	
	 /s/ Irwin Heller

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Hercules Technology Growth Capital, Inc.

	Printed Name of Stockholder
	
	 /s/ K. Nicholas Martitsch

	Signature of Stockholder

  

			
		 	K. Nicholas Martitsch
	Title:	 	 Associate General Counsel

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 October 29, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 

The Ingram Family Trust U/A/D 11/23/96 as amended 

	
	Printed Name of Stockholder
	
	 /s/ Gregory J. Ingram

	Signature of Stockholder

  

			
	Title:	 	 Trustee

 

			
	Address:	 	 The Ingram Family Trust

		
		 	 Attn: Gregory J. Ingram, TTEE

		
		 	  

	
	 Copy of all correspondence to:

		
		 	 The Ingram Family Trust

		
		 	 Attn: Diane Larson, Financial Mgr.

		
		 	  

		
		 	  

 

			
	Date:	 	 10/25/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Anthony John Khuri

	Printed Name of Stockholder
	
	 /s/ Anthony John Khuri

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Louis Lacasse

	Printed Name of Stockholder
	
	 /s/ Louis Lacasse

	Signature of Stockholder

  

			
		 	Louis Lacasse,
		 	    President
	Title:	 	 Genechem Management Inc.

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 Oct. 25, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Kevin J. Canning

	Printed Name of Stockholder
	
	 /s/ Kevin J. Canning

	Signature of Stockholder

  

			
	Title:	 	 Partner at Lahne and Manager of the
LLC

  

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Peter Lawrence

	Printed Name of Stockholder
	
	 /s/ Peter Lawrence

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Jay A. Levy

	Printed Name of Stockholder
	
	 /s/ Jay A. Levy

	Signature of Stockholder

  

			
	Title:	 	 Prof of Medicine

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Jay Levy/Sharon Levy

	Printed Name of Stockholder
	
	 /s/ Jay Levy /s/ Sharon Levy

	Signature of Stockholder

  

			
	Title:	 	 Shareholder

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/27/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	Jay Howard Linn, Trustee
	 Irrevocable Trust Agreement Number 1

	Printed Name of Stockholder
	
	 /s/ Jay Howard Linn

	Signature of Stockholder

  

			
	Title:	 	 Trustee

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 Oct 21 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Ralph A. Loren

	Printed Name of Stockholder
	
	 /s/ Ralph A. Loren

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 22 October 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Merifin Capital N.V.

	Printed Name of Stockholder
	
	by: Finabel S.A., Management Director
	 /s/ Guillaume de Rham
 by: Guillaume de Rham, Director

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	 c/o Finabel SA

		
		 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 26 October 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Mintz Levin Investments, LLC

	Printed Name of Stockholder
	
	 /s/ Jeffrey M. Wiesen, Manager

	Signature of Stockholder

  

			
	Title:	 	 Manager

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 October 20, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Nomura International PLC

	Printed Name of Stockholder
	
	 /s/ Denise Pallard-Knight

	Signature of Stockholder

  

			
	Title:	 	 Managing Director

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 27th October 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Nomura Phase4 Ventures LP

	Printed Name of Stockholder
	
	 /s/ Denise Pallard-Knight

	Signature of Stockholder
	 Nomura Phase4 Ventures Limited

as Manager of Nomura Phase4 Ventures LP

  

			
	Title:	 	 Managing Director

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 27th October 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 David Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 

Novack Family 1999 Trust f/b/o Emily Kate Novack 

	
	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Emily K. Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Helen Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Novack Family 1999 Trust f/b/o Jeffrey Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Jeffrey N. Novack 1996 Trust

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Kenneth J. Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Kenneth J. Novack 1993 Revocable Trust

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Marianne M. Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Sara E. Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	
Novack Family 1999 Trust f/b/o Sarah Elizabeth Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 The Osgood Family Trust UAD 4/14/2000

	Printed Name of Stockholder
	
	 /s/ Richard H. Osgood, Trustee

	Signature of Stockholder

  

			
	Title:	 	 The Osgood Family Trust UAD
4/14/2000

  

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/27/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 David Pastel

	Printed Name of Stockholder
	
	 /s/ David Pastel

	Signature of Stockholder

  

			
	Title:	 	 Mr. David Pastel c/o Levy

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/27/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Donald J.M. Phillips

	Printed Name of Stockholder
	
	 /s/ Donald J.M. Phillips

	Signature of Stockholder

  

			
	Title:	 	 CEO

 

			
	Address:	 	 Vox MEDICA

		
		 	  

		
		 	  

 

			
	Date:	 	 10/22/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Novack Family 1999 Trust f/b/o Laura Pontin

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Laura Novack Pontin

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Madeline Gunilla Pontin 1997 Present Interest Trust

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 POD Venture Partners AB

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 R. Robert Popeo

	Printed Name of Stockholder
	
	 /s/ R. Robert Popeo

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 PRAG Associates LLC

	Printed Name of Stockholder
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Agent

 

			
	Address:	 	 RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Suzanne Priebatsch

	Printed Name of Stockholder
	
	 /s/ Suzanne Priebatsch

	Signature of Stockholder

  

			
	Title:	 	 Norman and Suzanne
Priebatsch

  

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/25/2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Robert D. Ritchie

	Printed Name of Stockholder
	
	 /s/ Robert D. Ritchie

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 21 Oct 10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Rockwood Capital Corporation

	Printed Name of Stockholder
	
	 /s/ David H. Carl

	Signature of Stockholder

  

			
	Title:	 	 President

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 July and Peter Smith

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Beryl L. Snyder, Executrix

	Printed Name of Stockholder
	
	 /s/ Beryl L. Snyder, Executrix

	Signature of Stockholder

  

			
	Title:	 	 Executrix

 

			
	Address:	 	 Estate of Harold Snyder

		
		 	  

		
		 	  

 

			
	Date:	 	 October 26, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Patricia A. Suzman

	Printed Name of Stockholder
	
	 /s/ Patricia A. Suzman

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/23/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

			
	 Wheatley Medtech Partners, L.P.

	Printed Name of Stockholder
	
	 /s/ Barry Rubenstein

	Signature of Stockholder
		
	By:	 	Barry Rubenstein

  

			
		 	CEO, Wheatley Medtech Partners, LLC,
	Title:	 	 General Partner

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Miriam and Steven White

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	Winchester Capital Technology Partners LLC
and Winchester Capital Healthcare Partners LLC
	 Ceasar N. Anquillare

	Printed Name of Stockholder
	
	 /s/ Ceasar N. Anquillare

	 Signature of Stockholder

  

			
	Title:	 	 President & CEO

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 11/10/10

  
 4 

 EXHIBIT A 

PARATEK PHARMACEUTICALS, INC. 
 INSTRUMENT OF ADHERENCE 
 TO THIRD AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT 
 By execution and delivery of this signature page, Phase4 Ventures III LP hereby agrees to become a party to
that certain Third Amended and Restated Investor Rights Agreement (the “Investor Rights Agreement”) by and among Paratek Pharmaceuticals, Inc., a Delaware corporation, (the “Company”) and the Stockholders (as defined in the
Investor Rights Agreement), dated as of October 19, 2007, as amended, and is entitled to all of the benefits under and subject to all of the obligations, restrictions and limitations set forth in the Investor Rights Agreement that are
applicable to the Stockholders generally, and to Series C Investors, Series D Investors and Series H Investors in particular. This Instrument of Adherence shall take effect and shall become a part of said Investor Rights Agreement immediately upon
execution. 
 Executed, in counterpart, as of the date set forth below. 

 

			
	Phase4 Ventures III LP
	
	  

	By:	 	
	Its:	 	
		
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  

			
	Accepted:
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	  

		 	Thomas J. Bigger
		 	President and Chief Executive Officer

  
 Exhibit A-1

 EXHIBIT B 

SERIES C INVESTORS 

Nomura International plc 
 Omega Fund III, L.P.

 c/o Omega Fund Management Limited 

FSC Corp. 
 Kenneth J. Novack 

Becky Levin 
 Bio Fund Ventures II Ky

 K/S Danish BioVenture 
 Merifin
Capital N.V. 
 c/o Finabel S.A. 

Harold Snyder 
 c/o HBJ Investments, LLC

  
 Exhibit B-1

 HBJ Investments, LLC 
 Mintz Levin Investment LLC 
 c/o Mintz, Levin, Cohn, Ferris, 

      Glovsky and Popeo, P.C. 
 Irrevocable Trust Agreement Number I, Jay Howard Linn, Trustee 
 Norman and Suzanne Priebatsch

 Robert D. Ritchie 
 Barclays
Capital Inc. as Custodian for David Pastel IRA No.  
 Attn:  Louis Maione 

Winchester Capital Healthcare Partners LLC 
 c/o
Pensar N. Anquillare, President 
 Barclays Capital Inc. as Custodian for Frederick Frank IRA No.  

Attn:  Louis Maione 
 Jay and Sharon
Levy 
 R. Ellen and Mario Koenig 

  
 Exhibit B-2

 Miriam and Steven White 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Helen Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

David Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Judy and Peter Smith 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Novack Associates Limited Partnership II 
 c/o
RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Marianne M. Novack 
 c/o RINET Company, LLC 

Attn:  Patrick B. Maraghy 
 Kenneth J.
Novack 1993 Revocable Trust 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

  
 Exhibit B-3

 Novack Family 1999 Trust f/b/o 
 Emily K. Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Novack Family 1999 Trust f/b/o Jeffrey Novack 

c/o RINET Company, LLC 
 Attn:  Patrick
B. Maraghy 
 Novack Family 1999 Trust f/b/o Sara Elizabeth Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Novack Family 1999 Trust f/b/o Laura Pontin 

c/o RINET Company, LLC 
 Attn:  Patrick
B. Maraghy 
 Anthony John Khuri 
 c/o
Khuri Consulting Group 
 Donald J. M. Phillips 
 c/o Ted Thomas Associates 

  
 Exhibit B-4

 EXHIBIT C 

SERIES D INVESTORS 

Novartis BioVentures Ltd. 
 HBM BioVentures
(Cayman) Ltd. 
 Attention John Arnold 

Kenneth J. Novack 
 L&C Participation, LLC

 Ralph A. Loren, Personal 
 DeAnn F.
Smith, Personal 
 Formosa Healthcare Investments, L.P. 
 c/o Howard Lee, Ph.D. 
 Managing Director 
 Silver Biotech Management, Inc. 

  
 Exhibit C-1

 Wheatley MedTech Partners, LP 
 Attention:  Maureen Wilson 

			
	        With copies to:	  	 Wheatley Partners
 Attention:
David R. Dantzker, MD / Lawrence Wagenberg

 FSC Corp. 
 c/o
BancBoston Capital Inc. 
 Attention:  John J. Quintal 
 Alden I. Gifford 
 Rockwood Capital Corporation 

c/o David H. Carts 
 William G. Coughlin

 Barclays Capital Inc. as Custodian for David Pastel IRA 
 Attn:  Louis Maione 
 BioVeda Fund Pte Ltd 

Attention:  Damien Lim 
 R. Ellen and
Mario Koenig 

  
 Exhibit C-2

 Barclays Capital Inc. as Custodian for Sharon Levy IRA No. 

Attn:  Louis Maione 
 Barclays Capital
Inc. as Custodian for Jay Levy IRA No.  
 Attn:  Louis Maione 
 Anthony Khuri 
 c/o Khuri Consulting Group 

Robert Ritchie 
 Peter S. Lawrence 

GeneChem Therapeutics 
 Venture Fund L.P

 Nomura International PLC 
 Mintz
Levin Investments, LLC 
 Mintz, Levin, Cohn, 
         Ferris, Glovsky and Popeo, P.C. 
 Irwin Heller

 Harold Snyder 

  
 Exhibit C-3

 HBJ Investments, LLC 
 PRAG Associates LLC 
 c/o RINET Company, LLC 

Attn:  Patrick B. Maraghy 
 Merifin
Capital N.V. 
 c/o Finabel SA 
 Omega
Fund III, L.P. 
 c/o Omega Fund Management Limited 
 Winchester Capital Technology 
 Partners LLC 

David R. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Peter and Judy Smith 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Steven and Miriam White 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

  
 Exhibit C-4

 Helen Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

K/S Danish Bioventure 
  

			
	Coller International Partners IV Limited	  	Copy to: Coller Capital
	c/o Coller Capital	  	Attn:  Hiro Mizuno, Remdo Haaxman
	Attention Mr. Paul McDonald	  	and Laura Bradshaw

 POD Venture Partners AB (Reg. No. 556744-9441) 
 Attention Axel Roos 
 Robert E. Cawthorne 

Bio Fund Ventures II L.P. 
 Squamata Limited

  
 Exhibit C-5

 EXHIBIT D 

SERIES F INVESTORS 

POD 1.0 AB (Reg No. 556744-9441) 
 Attention
Axel Roos 
 Novartis BioVentures Ltd. 

Frederick Frank 
 Anthony John Khuri

 Khuri Consulting Group 
 R. Robert
Popeo 
 Robert Cawthorn 
 Peter S.
Lawrence 
 L&C Participation, LLC 

DeAnn F. Smith, PERSONAL 

  
 Exhibit D-1

 Kenneth J. Novack 
 David Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Jeffrey N. Novack 1996 Irrevocable Trust dated 2/14/96,
Marianne M. Novack, David R. 
 Novack and Paul D. Bishop, Trustee 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Judy and Peter Smith 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Helen Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Miriam and Steven White 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Emily K. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Sara E. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

  
 Exhibit D-2

 Madeline Gunilla Pontin 1997 Trust 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Laura Novack Pontin 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Omega Fund III, L.P. 
 c/o Omega Fund Management
Limited 
 BioVeda Fund Pte Ltd 

Attention:  Damien Lim, Ph.D. 

BioFund Ventures II Follow-On Fund L.P. 

Wheatley Med Tech Partners, LP 

Attention:  Maureen Wilson 

			
	        With copies to:	  	 Wheatley Partners

Attention:  David R. Dantzker, MD / Lawrence Wagenberg

 Rosemary Nguyen 

  
 Exhibit D-3

 EXHIBIT E 

SERIES H INVESTORS 

Aisling Capital II, LP 
 Aisling Capital

 Attn:  Anthony Sun 

        With a copy to: 
                 McDermott Will & Emery 
                 Attn:  Todd A. Finger 
 D.E. Shaw Valence Portfolios, L.L.C. 
 Attn:  James Mackey 

Hercules Technology Growth Capital, Inc. 

Attn:  Scott Harvey 
 Boston Life
Science Venture Corp. 
 Attn:  Dr. William Chung 
 Thomas J. Dietz 
 c/o Wedbush Morgan Securities 

Attention Kathleen Shea 
 The Osgood Family
Trust UAD 4/14/2000 
 c/o Wedbush Morgan Securities 
 Attention Kathleen Shea 

  
 Exhibit E-1

 The Osgood Family Trust UAD 4/14/2000 
 c/o Wedbush Morgan Securities 
 Attention Kathleen Shea 

Ben Perkins Custodian for William Beau Perkins Uniform Gift to Minors Act CA 
 c/o Wedbush Morgan Securities 
 Attention Kathleen Shea 

Ben Perkins Custodian for Charlotte Rose Perkins Uniform Gift to Minors Act CA 
 c/o Wedbush Morgan Securities 
 Attention Kathleen Shea 

The Ingram Family Trust U/A/D 11/23/96, as amended, Gregory J. Ingram & Heidi M. Ingram, 

Trustees 
 c/o Wedbush’Morgan Securities

 Attention Kathleen Shea 
 Sarah L.
Gordon 
 Novartis BioVentures Ltd 

Attn:  Emil Bock 
 Nomura Phase4
Ventures LP 
 Attn:  Dr. Denise Pollard-Knight 
 Bio Fund Ventures II Follow-On L.P. 
 Attn:  Kalevi Kurkijarri 

  
 Exhibit E-2

 HBM BioVentures (Cayman) Ltd. 
 Attn:  John Arnold 
 Omega Fund III, L.P. 

c/o Omega Fund Management Limited 
 BioVeda Fund
Pte Ltd 
 Attn:  Damien Lim, Ph.D. 
 Kenneth J. Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 PRAG Associates LLC 

c/o RINET Company, LLC 
 Attn:  Patrick
B. Maraghy 
 Jeffrey N. Novack 1996 Trust 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Emily K. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Sara E. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

  
 Exhibit E-3

 Madeline Gunilla Pontin 1997 Present Interest Trust 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

David Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Judy & Peter Smith 
 c/o RINET Company,
LLC 
 Attn:  Patrick B. Maraghy 
 Novack Family 1999 Trust f/b/o Emily Kate Novack 
 c/o RINET Company, LLC 

Attn:  Patrick B. Maraghy 
 Novack
Family 1999 Trust f/b/o Jeffrey Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Novack Family 1999 Trust f/b/o Sarah Elizabeth Novack

 c/o RINET Company, LLC 

Attn:  Patrick B. Maraghy 
 Novack
Family 1999 Trust f/b/o Laura Pontin 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Helen Novack 

c/o RINET Company LLC 
 101 Federal Street

 Boston, MA 02110 

Attn:  Patrick B. Maraghy 

  
 Exhibit E-4

 Miriam and Steven White 
 Boston, MA 02110 
 Attn:  Patrick B. Maraghy 

Laura Novack Pontin 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

David and Lesley Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Marianne M. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Peter S. Lawrence 
 Patricia A. Suzman

 John P. Dunphy 
 KC Stone

 c/o Wedbush Morgan Securities 

Attention Kathleen Shea 

  
 Exhibit E-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]